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Abstract
Adeno-associated viral (AAV) vectors show great potential for therapeutic gene delivery for monogenic
diseases, including hemophilia. Major limitations of this approach are the inability to persist in dividing
cells and the restrictive packaging capacity of AAV. Gene targeting, the ability to make site-directed
changes to the genome, has been a powerful tool for genetic discovery. Until recently, the low efficiency of
targeting has rendered it unlikely to be of therapeutic value for most genetic diseases. Zinc finger
nucleases (ZFNs) are engineered proteins capable of site-directed DNA cleavage, known to increase the
efficiency of gene targeting. Our lab has previously demonstrated in vivo gene targeting of the liver using
AAV to deliver ZFNs and therapeutic donor in neonatal mice, where the rapid proliferation of hepatocytes
may promote genome editing through homology directed repair (HDR). It was unknown whether the
success of this approach could be replicated in adult mice (with predominantly quiescent hepatocytes,
unlikely to be amenable to HDR). We hypothesized that in the absence of HDR, the non-homologous endjoining (NHEJ) pathway may promote gene targeting in adult mice. Indeed, homology independent vector
integration was sufficient to drive robust expression of clotting factor IX, deficient in hemophilia B, and
correct the disease phenotype in mice treated as adults. This approach was adapted to create a general
platform for liver-directed protein replacement therapy. Using ZFNs targeting the mouse albumin locus,
we achieved long-term therapeutic expression of human factors VIII and IX in mouse models of
hemophilia A and B as well as four different therapeutic enzymes deficient in lysosomal storage
disorders. To test our hypothesis that in vivo genome editing relies on different DNA repair mechanisms
in neonatal and adult mice, we applied multiple techniques including a novel reporter construct, southern
blot, comparisons of donors with and without arms of homology, and a mouse model of NHEJ deficiency.
These data indicate HDR is the primary mechanism of genome editing in neonatal mouse livers, and
dispensable for therapeutically relevant levels of genome editing in adult mice. These results have
implications in designing safer and more efficacious genome editing therapies.
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ABSTRACT
IN VIVO GENOME EDITING: PROOF OF CONCEPT IN
NEONATAL AND ADULT MOUSE LIVER
Rajiv Sharma
Katherine A. High

Adeno-associated viral (AAV) vectors show great potential for therapeutic gene delivery
for monogenic diseases, including hemophilia. Major limitations of this approach are the
inability to persist in dividing cells and the restrictive packaging capacity of AAV. Gene
targeting, the ability to make site-directed changes to the genome, has been a powerful
tool for genetic discovery. Until recently, the low efficiency of targeting has rendered it
unlikely to be of therapeutic value for most genetic diseases. Zinc finger nucleases
(ZFNs) are engineered proteins capable of site-directed DNA cleavage, known to
increase the efficiency of gene targeting. Our lab has previously demonstrated in vivo
gene targeting of the liver using AAV to deliver ZFNs and therapeutic donor in neonatal
mice, where the rapid proliferation of hepatocytes may promote genome editing through
homology directed repair (HDR). It was unknown whether the success of this approach
could be replicated in adult mice (with predominantly quiescent hepatocytes, unlikely to
be amenable to HDR). We hypothesized that in the absence of HDR, the nonhomologous end-joining (NHEJ) pathway may promote gene targeting in adult mice.
Indeed, homology independent vector integration was sufficient to drive robust
expression of clotting factor IX, deficient in hemophilia B, and correct the disease
phenotype in mice treated as adults. This approach was adapted to create a general
platform for liver-directed protein replacement therapy. Using ZFNs targeting the mouse
v

albumin locus, we achieved long-term therapeutic expression of human factors VIII and
IX in mouse models of hemophilia A and B as well as four different therapeutic enzymes
deficient in lysosomal storage disorders. To test our hypothesis that in vivo genome
editing relies on different DNA repair mechanisms in neonatal and adult mice, we applied
multiple techniques including a novel reporter construct, southern blot, comparisons of
donors with and without arms of homology, and a mouse model of NHEJ deficiency.
These data indicate HDR is the primary mechanism of genome editing in neonatal
mouse livers, and dispensable for therapeutically relevant levels of genome editing in
adult mice. These results have implications in designing safer and more efficacious
genome editing therapies.
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CHAPTER 1: INTRODUCTION
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Gene Therapy
Gene therapy, the transfer genetic material to correct or ameliorate disease, has
made major progress in the last few decades. The modern concept of using viral vectors
to transfer genes was first proposed in 1972 (Aposhian, Qasba, Osterman, & Waddell,
1972), and since then the investment in resources as well as advances in our
understanding of biological principles have culminated in promising clinical trials results.
Among the first candidates for the development of these novel therapies were
monogenic

diseases

that

cause

immunodeficiencies,

inherited

blindness,

and

hemophilia.
Retroviral Vectors
Early studies demonstrating the use of retroviruses as a gene transfer agent
were published in the early 1980s (Shimotohno & Temin, 1981; Tabin, Hoffmann, Goff, &
Weinberg, 1982; Wei, Gibson, Spear, & Scolnick, 1981). These tools improved rapidly,
due in large part to the retroviral virology of the prior decade, with the development of
non-infectious vector systems and stable packaging lines (Mann, Mulligan, & Baltimore,
1983; Markowitz, Goff, & Bank, 1988; Miller & Buttimore, 1986). These vectors emerged
as a highly capable method of transduction of many different cell lines and primary cell
types in vitro.
Gene therapy for SCID-X1
The severe combined immunodeficiency characteristic of X-linked SCID disease
is caused by a deficiency in the “common gamma” cytokine receptor (IL2RG) and is in
many ways an ideal target for gene therapy. The devastating disease results in a
2

complete lack of T and NK cell subsets within the immune system (Noguchi et al., 1993).
Due to the lack of T cell “help,” deficient B cell antibody production renders patients
susceptible to many opportunistic infections. Allogeneic bone marrow transplant, the only
known cure, is not possible in all circumstances. The etiology of SCID-X1 is well
characterized, and, based on data from animal models and in human cells, introduction
of a wild-type IL2RG gene to a patient’s own hematopoietic stem cells (HSCs) would be
expected to restore functional signaling through IL-2, 4, 7, 9, 15, and 21 receptors (which
all form complexes with the gamma chain) and rescue the disease phenotype. The
successfully transduced cells are endowed with a competitive advantage over those that
harbor the defective gene, and are able to expand by several orders of magnitude to
reconstitute the immune system with functional B, T, and NK cells.
The first trials were conducted with gamma retroviral vectors to deliver the IL2RG
gene, and corrected HSCs were successful in reconstituting the immune systems of
most patients (Cavazzana-Calvo et al., 2000; Howe et al., 2008). Unfortunately, the
treatment was also associated with leukemia in 25% of the 20 subjects treated. The
proposed mechanism of this adverse event was the integration of the vector used to
deliver IL2RG in the vicinity of oncogenes, causing upregulation (Howe et al., 2008);
reviewed in (Bushman, 2014). This hypothesis was supported by studies demonstrating
integration of the retroviral provirus within the first intron of the LMO-2 gene, and
upregulation of expression of LMO-2, previously shown to be upregulated in T cell
leukemias (Rabbitts et al., 1999). Although four of these five patients’ leukemias were
treatable, it became clear that insertional oncogenesis would be the most important
safety concern for gene therapies that modify the genome. Going forward, developments
3

in vector technology such as the inclusion of insulator sequences and replacing retroviral
vectors with HIV-based lentiviral vectors (which are thought to have integration
preferences less compatible with transformation) have been incorporated to treat other
immunodeficiencies and thalassemia. These design changes appear to lessen, but not
completely remove, the risk of uncontrolled proliferation due to insertional mutagenesis.
These results in patients make the strongest empirical case for the development of
methods to increase the specificity of DNA targeting in diseases that require an
integrated copy of the corrective gene.
AAV Vectors
As opposed to retroviral vectors, adeno-associated viral vectors (AAV) are
primarily non-integrating, persisting mainly in the form of extrachromosomal “episomes”
outside of the genome. AAV was originally discovered as a contaminant in adenoviral
cell cultures, and researchers have since discovered hundreds of natural variants
differing primarily in capsid structure. Various serotypes (namely AAV2 and AAV8) have
emerged as a highly efficient means to deliver genetic material to multiple tissues. The
virus contains three capsid proteins (VP1, VP2, VP3) at a 5:5:50 ratio in a T=1
icosahedral structure, which encapsulate a single stranded genome of roughly 4.7kb.
The only cis requirements for packaging are the inverted terminal repeat (ITR)
sequences on each end of the viral genome, meaning the viral genes can be substituted
with other sequences to create a viral vector. Recombinant vector can be produced in
cell culture by triple transfection of: (i) helper plasmid (as a dependovirus, AAV requires
elements from other viruses such as adenovirus), (ii) wild type AAV genes encoding Rep
and Cap, and (iii) the vector genome flanked by ITRs. Upon reaching the nucleus of
4

target cells, vectors uncoat, releasing their vector genome, which will persist
predominantly in the form of concatamers joined together end to end (Duan, Yue, &
Engelhardt, 2003; Yang et al., 1999).
Due to the AAV genome’s low rate of integration and inability to actively
segregate with centromeres upon cell division, expression is lost dramatically upon cell
division. Cells that undergo even small numbers of divisions exhibit a considerable
reduction in AAV expression. As a result, standard AAV approaches are poorly suited to
treat immune deficiencies or other diseases in which cells need to divide substantially
after treatment. However, gene delivery with AAV is ideal for targeting organs such as
liver, muscle, or brain, which do not typically divide and are not amenable to ex vivo
manipulation, and for diseases in which the target cells do not typically divide.
Hemophilia
Hemophilia B, an inherited bleeding disorder caused by mutations in the Factor 9
(F9) gene results in deficiency of the Factor IX (F.IX) enzyme within the clotting cascade.
Hemophilic patients harboring mutations in F9 have been treated with blood transfusions
or protein replacement therapy in which hF.IX protein is intravenously injected 2-3 times
per week. The cost of this prophylactic treatment with recombinant clotting factor can
exceed $250,000 per year for the life of the patient (Nathwani et al., 2014). Many
patients in developing countries cannot afford this treatment, and as a result are faced
with a shorter life expectancy. Even when receiving this therapeutic regimen, patients
remain at high risk for uncontrolled bleeds during intervals between protein therapy
infusions. Therefore, hemophilia is an excellent candidate for gene therapy, in which
5

stable production of the wild-type F9 gene could potentially cure a patient for life. One of
the major limitations to gene therapy has been the low efficiency of stable gene
expression leading to therapeutic levels of protein production in vivo. However,
hemophilia B is a particularly good candidate for gene therapy development as achieving
even 1% of normal hF.IX activity can greatly mitigate disease, and above 5% is
considered a mild phenotype, with far fewer bleeding risks in normal circumstances.
Most AAV serotypes, including the best characterized AAV2 and AAV8, are
particularly efficient in transducing liver, which, as a large and well-vascularized organ, is
proficient at secretion of multiple proteins present in the blood. In preclinical models
targeting quiescent adult livers, the predominantly non-integrating AAV vector supports
long-term expression of F.IX in murine, canine, and non-human primate models,
persisting for over 10 years. Clinical trials have shown great potential for AAV based
therapies in the treatment of hemophilia, demonstrating over 3 years of stable hF.IX
expression following a single infusion of AAV8 vector (Nathwani et al., 2014; 2011). It is
unknown whether stable AAV-mediated expression can be achieved in the clinic when
treating proliferating tissues, where a strategy based on chromosomal integration would
be ideal.
Genome Editing
Site-specific targeting of the genome has been used to disrupt as well as
introduce DNA into genes in mouse embryonic stem cells for nearly three decades. By
introducing DNA containing the intended payload flanked by sequences identical to the
target site (arms of homology), a small fraction of cells will incorporate the desired
6

changes into their genome (Thomas & Capecchi, 1987). Various strategies used to
overcome the low efficiency by selecting for targeted clones made it possible to expand
and characterize the edited cells. These methods fostered the development of
purposefully designed knock-out and knock-in mice, and have become a pillar in modern
biology. Site-specific correction of a mutated gene is in many ways the holy grail of gene
therapy. The corrected gene would be indistinguishable from a wild-type (non-diseased)
allele, and the resulting gene product would retain all of its natural regulatory
mechanisms. Unfortunately, the low absolute efficiency of the process meant it was
unlikely to find therapeutic application for most diseases.
Maria Jasin and colleagues noted that the targeting efficiency can be increased
by several orders of magnitude by creating a DNA break at the intended target site
(Rouet, Smih, & Jasin, 1994a). Following a DNA double strand break, the cell can utilize
one of two major pathways of repair: non-homologous end joining (NHEJ), and
homology directed repair (HDR). NHEJ is more active in mammalian cells, and as the
name implies does not require a homologous template, instead resolving the break by
ligating the free ends. The other pathway, HDR, is known to be upregulated during the S
and G2 phases of the cell cycle, when the sister chromatid is available as a template,
and is capable of both error free repair and gene targeting if a homologous donor is
provided as the repair template. (These mechanisms will be discussed in greater detail
in chapter 4). Historically, gene targeting has been used synonymously with one of the
two major DNA double strand break repair pathways: homology directed repair. The
other, non-homologous end-joining, is typically associated with mutagenic disruption of
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genes due to the fact that small (< 5) insertions and deletions of nucleotides are often
observed at sites of repetitive DNA cleavage.

Zinc Finger Nucleases
Zinc finger nucleases (ZFNs) are chimeric proteins that contain two linked
modules: a DNA binding domain and a DNA cleavage domain. These tools were
originally developed by Chandrasegaran and colleagues (Bibikova et al., 2001), and
were shown to be effective in stimulating homologous recombination in human cell lines
(Carroll, 2011; Porteus, Cathomen, Weitzman, & Baltimore, 2003) as well as primary
cells (Urnov et al., 2005). The DNA binding domain consists of multiple Cys2His2 zincfinger motifs often found in eukaryotic transcription factors, which each typically
recognize a 3bp DNA sequence (Figure 1.1). The DNA cleavage domain comes from
the bacterial FokI restriction enzyme, which must dimerize to create a double strand
break. Two ZFNs can bind neighboring DNA regions to bring the weakly interacting FokI
domains in close proximity (and thus a high local concentration) to achieve efficient
cleavage. Compared to the majority of bacterial restriction enzymes used in molecular
biology, which generally have a 4-8bp target, ZFNs are capable of much longer
recognition sequences to the point where they are likely to be unique in the large
mammalian genome. Assuming bases are distributed randomly, an 18bp address would
occur once in 6.8x1010 bp, compared to 3.5x109 bp in the human genome (Q. Liu, Segal,
Ghiara, Barbas, III, 1997). A pair of ZFNs, each with 4 ZF modules, can be generated to
target almost any existing gene.
8

Figure 1.1
ZFN Sche ma tic

AAV and Gene Targeting

AAV vectors can promote up to 1000-fold greater levels of genome editing
relative to plasmid DNA or other delivery vectors. This phenomenon appears to be only
partially explained simply by a high rate of transduction of many cell types. Multiple
attributes of the AAV vector may explain these incompletely understood observations. A
major difference between plasmids and AAV vector genomes is that standard AAV
genomes are single stranded, except for the ITRs on each end which form hairpins and
small stretches of double stranded DNA. Studies indicate that the unusual DNA
conformation is recognized as DNA damage (Hendrie, Hirata, & Russell, 2003; Hirata &
Russell, 2000), and suggests recruitment of proteins involved in HDR could increase the
likelihood of a cell using AAV as the template for repair.
In Vivo Genome Editing Using Zinc Finger Nucleases
Combining the tools for highly efficient gene delivery to the liver (AAV) and the
ability to generate site-directed DNA breaks (ZFNs), our lab demonstrated successful
genome editing in vivo in a mouse model of hemophilia B. The mouse model, designated
hF9mut, contained an truncated human F9 mini-gene under the control of a liver specific
enhancer and promoter. The strategy for in vivo genome editing involved co-delivery of
two AAV8 vectors: (i) Expressing a ZFN pair which targets intron 1 of the integrated
hF9mut cassette, and (ii) Donor containing a corrective therapeutic transgene, flanked
by arms of homology to the ZFN target site. By treating mice with these vectors at day 12 of life (as neonates), we observed secretion of human F.IX in the plasma of these mice
9

only when they were treated with both vectors, and only in mice that harbored the
hF9mut cassette (Li et al., 2011). Importantly, the process was efficient enough to
produce plasma hF.IX concentrations of over 200 ng/mL (4% of normal) and
phenotypically correct hemophilic mice, restoring their ability to form blood clots in a wellcharacterized in vitro assay (aPTT). These findings established that therapeutic benefit
could be achieved through targeted genome editing even without a selective advantage
for the gene-targeted cells.
Hypotheses and Rationale for Dissertation Studies
At the time these dissertation studies began, we were encouraged by the
success of in vivo genome editing in neonatal mice. At the same time, we began
generating data that suggested HDR was not the sole mechanism responsible for the
observed donor integration, as our donor design allowed for both vector integration and
HDR events to support expression of a functional hF.IX protein. We hypothesized that in
the absence of substantial cell proliferation, where HDR is not thought to be active, the
NHEJ pathway would promote site directed genome editing in adult mice. The goals of
the experiments presented in this dissertation were: a) To determine whether homology
independent mechanisms could permit therapeutic gene addition, which may be
necessary in quiescent adult livers, and b) To investigate the mechanisms of in vivo
genome editing.

10

CHAPTER 2: ROBUST ZFN-MEDIATED GENOME EDITING IN ADULT HEMOPHILIC MICE

This chapter was adapted from (Anguela et al., 2013)
11

Summary
Monogenic diseases, including hemophilia, represent ideal targets for genome
editing approaches aimed at correcting a defective gene. Here we report that systemic
adeno-associated viral vector (AAV) delivery of zinc finger nucleases (ZFNs) and
corrective donor template to the predominantly quiescent livers of adult mice enables
production of high levels of human Factor IX (hF.IX) in a murine model of hemophilia B.
Further, we show that off-target cleavage can be substantially reduced while maintaining
robust editing by using obligate heterodimeric ZFNs, engineered to minimize unwanted
cleavage due to homodimerization of the ZFNs. These results broaden the therapeutic
potential of AAV/ZFN mediated genome editing in the liver and could expand this
strategy to other non-replicating cell types.

12

Introduction

We previously reported successful in vivo gene targeting in a neonatal mouse
model of hemophilia B (HB). Specifically, we demonstrated that systemic co-delivery of
AAV vectors, encoding a ZFN pair targeting the human F9 gene (AAV-ZFN) and a gene
targeting vector with arms of homology flanking a corrective cDNA cassette (AAVDonor), resulted in the correction of a defective hF9 gene engineered into the mouse
genome (referred to as hF9mut locus) in the livers of neonatal HB mice. Importantly, we
obtained stable levels of hF.IX expression sufficient to normalize clotting times (Li et al.,
2011).
However, the neonatal model differs from the anticipated clinical setting
(Nathwani et al., 2011) in the degree of hepatocyte proliferation. While neonatal mouse
livers undergo multiple rounds of cell division during development, the rate of turnover in
adult hepatocytes is very low (Magami et al., 2002). In the quiescent or G0 phase of the
cell cycle, DNA double strand breaks (DSBs) such as those created by ZFNs are
expected to be repaired mainly by non-homologous end joining (NHEJ), one of two
major repair pathways (Branzei & Foiani, 2008; Moynahan & Jasin, 2010). Despite
NHEJ being the predominant repair choice in mammalian cells, few approaches have
exploited this mechanism. Genome editing has traditionally been considered
synonymous with the other repair pathway, homology directed repair (HDR), which is
mainly active in the S/G2 phases of the cell cycle. We therefore investigated whether
ZFN-driven gene targeting could be generalized to adult animals where the impact of a
largely quiescent liver could be assayed.
13

Materials and Methods

Animal experiments
Animal experiments were approved by the Institutional Animal Care and Use
Committee at the Children’s Hospital of Philadelphia. Previously described heterozygous
male hF9mut transgenic mice (Li et al., 2011) or wild type littermate controls, 8 to 10
weeks of age, were used. hF9mut/HB male mice were obtained by crossing male
homozygote hF9mut mice with previously described HB females (Li et al., 2011). Partial
hepatectomies were performed as previously described (Mitchell & Willenbring, 2008).
AAV vector was diluted to 200 μl with PBS + 0.001% Pluronics before tail-vein injection.
Plasma for human factor IX ELISA was obtained by retro-orbital bleeding into
heparinized capillary tubes. Plasma for aPTT was obtained by tail bleeding, 9:1 into
3.8% sodium citrate. Tissue for nucleic acid analysis was immediately frozen on dry ice
after necropsy.
ZFN reagents and targeting vectors
ZFNs targeting the hF9mut locus and F9 targeting vectors have been previously
described (Li et al., 2011), as well as the ELD:KKR mutations to the FokI domain to
construct the obligate heterodimeric ZFNs (Doyon et al., 2011). Experiments shown in
Figure 2.2 used the wild-type FokI domain with the exception of Figure 2.2D in which the
obligate heterodimeric ZFNs were used. AAV serotype 8 vectors were produced and
titered as previously described (Ayuso et al., 2009),(Wright & Zelenaia, 2011).
Factor IX levels and activity
14

Human factor IX ELISA kit (Affinity Biologicals; Ancaster, ON, Canada) was used
to quantify plasma hF.IX. All readings below the last value of the standard curve (15
ng/ml) were arbitrarily given the value of 15 ng/ml except where otherwise indicated. The
activated partial thromboplastin time (aPTT) assay was performed by mixing sample
plasma 1:1:1 with pooled hemophilia B human plasma (George King Biomedical, Inc.;
Overland Park, KS, USA) and aPTT reagent (Trinity Biotech; Bray, Wicklow, Ireland),
followed by a 180s incubation period at 37°C. Coagulation was initiated after the addition
of 25 mM calcium chloride. Time to clot formation was measured using a STart 4
coagulation instrument (Diagnostica Stago; Parsippany, NJ, USA).
PCR-based genotyping
Primers binding to a sequence upstream of exon 1 unique to the hF9mut minigene and within a sequence unique to the donor were used to amplify targeting events
from genomic DNA. Genomic DNA from mouse liver was isolated using the MasterPure
complete DNA purification kit (Epicentre Biotechnologies; Madison, WI, USA). To detect
the targeting of the donor cassette via NHEJ or HDR, gDNA was amplified using the P1
(5'ACGGTATCGATAAGCTTGATATCGAATTCTAG3')

and

P5

(5'GCCCTTCTGGAACTGGACGAACC3') primers binding respectively to a sequence
upstream of exon 1 unique to the hF9mut mini-gene and within a sequence unique to the
donor found in exon 8 of hF9. The PCR reactions were performed using Phusion Highfidelity DNA polymerase (New England BioLabs; Ipswich, MA, USA) in conjunction with
GC Buffer and 3% dimethylsulphoxide for 25 cycles (10" denaturation at 98°C, followed
by 1'50'' of extension at 65°C). The PCR products were then purified with G50 columns,
resolved by 5% PAGE and autoradiographed.
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Clustered integration site analysis (CLIS)
The mapping of in vivo ZFN cleavage sites was performed as previously
described4, using sequencing data from our previous study (Li et al., 2011). For a CLIS
to be scored required two integrations within 500bp in all six ZFN treated mice. This
analysis revealed nine potential ZFN off-target sites of which four were confirmed by CelI assays in adult mice treated with AAV8-ZFN (on target activity observed at >40%).
Surveyor nuclease (Cel-I) assay
Assay was performed as described previously (Doyon et al., 2011; Li et al.,
2011). Genomic DNA from mouse liver was isolated using the MasterPure complete
DNA purification kit (Epicentre Biotechnologies) and the assay was performed as
described previously (Doyon et al., 2011; Li et al., 2011). Loci were amplified for 30
cycles (60 °C annealing and 30" elongation at 68 °C). The following primers were used
for

Chr.1

(5'

GCAGAGAGTTCA

GGTCGCCTAGCC

3'

and

5'

TGAACCAGTCCATCAGCAGGTGAC 3'), Chr.2 (5' TCACCC TGCCTTGTTCCTCTGGA
3' and 5' ACCGAAAGCTCAGGCGGGTA 3'), Chr.6 (5' TGGGAGCGTCATCGTGGGTC
3'

and

5'

CCGGCAAAGCAAAGAGGTTCGC

3'),

Chr.13

(5'

TGACAAGGGACGCATCACCCGA 3' and 5' AGGGGCAGTGAAGAGACTCATGTGG 3'),
and

the

hF9mut

locus

(5'

CTAGTAGCTGACAGTACC

3'

and

5'

GAAGAACAGAAGCCTAATTA TG 3').
Liver function tests
Quantification of plasma alanine aminotransferase (ALT) was performed using an
ALT colorimetric assay (Teco Diagnostics; Anaheim, CA, USA).
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IHC analysis
IHC staining was performed using Ki-67 antibody (abcam ab16667) to stain
formalin-fixed, paraffin embedded tissue. Ki67 antibody (Abcam ab16667; Cambridge,
UK) was used to stain formalin-fixed, paraffin–embedded tissue. Parraffin was cleared
with xylene and slides were rehydrated through descending concentrations of ethanol.
Slides were then treated with 3% H2O2/methanol for 30min. Sides were pretreated in a
pressure cooker (Biocare medical; Concord, CA, USA) in Antigen Unmasking solution
(Vector Labs H3300; Burlingame, CA, USA). Slides were rinsed in 0.1M Tris Buffer then
blocked with 2% fetal bovine serum for 15 min. Slides were additionally blocked for
endogenous biotin using the avidin biotin blocking kit (Vector Labs SP2001). Slides were
then incubated with Ki67 antibody at a 1:400 dilution for 1hr at room temperature. Slides
were again rinsed then incubated with biotinylated anti-rabbit IgG 1:200 dilution (Vector
Labs) for 30min at room temperature. After rinsing, slides were then incubated with the
avidin biotin complex (Vector Labs) for 30 min at room temperature. Slides were then
rinsed and incubated with DAB (DAKO Cytomation; Carpinteria, CA, USA) for 10 min. at
room temperature. Slides were then rinsed and counterstained with Hematoxylin (Fisher
Scientific) for approximately 30 seconds, then rinsed, dehydrated through a series of
ascending concentrations of ethanol and xylene, then coverslipped. Stained slides were
scanned at 20x magnification using an Aperio ScanScope OS slide scanner. Aperio’s
Image Analysis Toolkit was used to score a minimum of 90,000 nuclei (Nuclear v9
algorithm) to quantify the percentage of Ki-67+ nuclei.
RT-PCR
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Tissues were homogenized in Qiazol and cellular RNA was isolated with
miRNeasy Mini kits (Qiagen; Valencia, CA, USA), treated with DNaseI (Life
Technologies; Carlsbad, CA, USA) and 1µg reverse-transcribed using the High Capacity
RNA-to-cDNA Kit (Life Technologies). PCR was performed using AccuPrime Pfx
SuperMix (Life Technologies). The following pairs of primers were used: hF9Fw (5’
CCTCATCACCATCTGCCTTT 3’), which anneals to exon 1 within the hF9mut genomic
locus, and hF9Rv (5’ GGGCAGCAGTTACAATCCAT 3’), that anneals to exon 7 in the
AAV Donor; Gapdh1 (5’ CTCTCAATGACAACTTTGTCAAG 3’) and Gapdh2 (5’
TCCTTGGAGGCCATGTAGGC 3’). The following cycling conditions were used: 95°C for
10 min, followed by 35 cycles of 95°C for 30”, 60°C for 60” and 68°C for 60”.
qRT-PCR
qPCR was performed using Ambion’s High Capacity RNA-to-cDNA and Fast
SYBR Green Master Mix (Applied Biosystems; Foster City, CA, USA) according to
manufacturers instructions. The following primers were used: mFATP2-Fw (5’
CAACATTCGTGCCAAGTCTC 3’), mFATP2-Rv (5’ GACACGGCATCCTTTTTCAG 3’),
mFATP2-Mut-Rv (5’ TACCTCTTTGGCCGATTCAG 3’). Cycling conditions were: 95°C
for 2’, followed by 40 cycles of 95°C for 15 s, 60°C for 30”.
Statistics
Graphpad Prism was used to perform all the statistical tests. If data passed the
D’Agostino & Pearson normality test, then a two-sided t-test was used. Otherwise, the
nonparametric Mann-Whitney test (two-tailed) was used. In all tests, p<0.05 was
considered significant.
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Results
Eight week-old hF9mut mice (harboring the ZFN target site) were treated with
1x1011 vg of AAV-ZFN, expressing the hF9 specific ZFN pair and 5x1011 vg of AAVDonor, containing arms of homology flanking the corrective partial cDNA cassette
(Figure 2.1). Treated animals exhibited long term expression (>60 weeks) of hF.IX
averaging 23% of normal (1146±100 ng/mL) at week 60 (Figure 2.2A). In contrast,
plasma hF.IX levels in mice co-injected with a luciferase expressing AAV-Mock vector
and AAV-Donor or mice injected with AAV-ZFN alone were below the limit of detection
(15 ng/mL) (Figure 2.2A). Treatment of hF9mut/HB mice with AAV-ZFN and AAV-Donor
produced similarly high hF.IX expression levels (Figure 2.2B) and reduced clotting times
to those of WT mice (Figure 2.2C). Mice aged 7-8 months at initial injection exhibited
lower but nonetheless therapeutic levels of hF.IX (Figure 2.3). hF.IX expression was
derived predominantly from stably integrated, on-target gene correction based on two
independent observations. First, following 2/3 partial hepatectomy (PHx), known to
induce hepatocyte proliferation and subsequent loss of episomal AAV genomes(Song et
al., 2004), plasma hF.IX levels were not reduced (Figure 2.2D). Second, treatment of
wild-type littermates lacking the hF9mut locus (and therefore the ZFN target site)
supported just ~50 ng/mL hF.IX (Figure 2.2E). As predicted by the use of a liver-specific
promoter to drive ZFN expression and the hepatotropism of the AAV8 serotype, hF9
mRNA was exclusively detected in the liver and only when both the ZFN and Donor
vectors were administered (Figure 2.4). Proliferation levels in adult mouse liver were
confirmed to be low by Ki-67 staining shortly after treatment (Figure 2.5). Nonquantitative PCR-based molecular analyses 5 months post injection revealed gene
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insertion in the liver through both homology-directed and homology independent
processes precisely at the ZFN-specified locus, each of which is predicted to result in
hF.IX expression (Figure 2.2F and Figure 2.6). We next sought to determine the impact
of arms of homology on genome editing. We measured hF.IX levels resulting from
treatment of hF9mut mice with ZFN and donors containing no substantial homology to
the target site, establishing that homology arms are not required for clinically meaningful
levels of correction (Figure 2.7). Together these data demonstrate that nuclease-driven
gene targeting in the quiescent livers of adult mice via IV administration of AAV vectors
results in substantial levels of hF.IX, sufficient to correct the phenotypic defect in
hemophilia B mice.
For therapeutic application the risk of ZFN cleavage at off target sites should be
minimized. To assay off-target activity we first identified potential cleavage sites using a
genome-wide clustered integration site (CLIS) analysis (Gabriel et al., 2011) of 454 deep
sequencing data from our previous in vivo ZFN study (Li et al., 2011). To identify
integration sites attributed to ZFN activity, we compared integration sites in ZFN- versus
Mock-treated animals, excluded those common to both groups of mice, which generated
a list of nine potential off-target sites in the ZFN-treated mice. Next, using the Cel-I assay
(Perez et al., 2008) we confirmed four of these sites as bona fide targets of ZFN
cleavage in livers of mice treated with AAV-ZFN at week 4 post treatment (Figure 2.8A).
Since all four cleavage sites mapped to a ZFN target sequence resulting from the
homodimerization of one of the two ZFNs we constructed an AAV-ZFN vector employing
an obligate heterodimeric FokI architecture containing the ELD:KKR mutations in the
dimerization interface between the two ZFNs to reduce cleavage (Doyon et al., 2011).
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On target activity was similar for the WT and ELD:KKR ZFNs as measured by the levels
of hF.IX expression (Figure 2.8B) and cleavage at the hF9mut locus at week 4 post
treatment (Figure 2.8C). In hF9mut mice treated with the obligate heterodimeric AAVZFNELD:KKR vector, the levels of off-target cleavage/repair were significantly reduced
(relative to AAV-ZFNWT controls) at all sites analyzed (Figure 2.8A). Consistent with this
reduction in off-target cleavage, the low background levels of hF.IX expression observed
in

AAV-ZFNWT treated mice that lack the hF9mut locus, potentially arising from an

integration event on chr2 (Figure 2.9), were reduced to below our limit of detection by
the ELD:KKR variants (Figure 2.8D). Thus, while the use of WT ZFNs appears to be
well tolerated, producing stable hF.IX expression over 60 weeks without change in
circulating liver enzymes (Figure 2.2A, Figure 2.10), these data support the use of the
obligate heterodimeric ZFNs which provide an increase in specificity without reducing
hF.IX expression.
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Discussion
In summary, these data provide the first demonstration of robust in vivo genome editing
in the context of the predominantly quiescent hepatocytes of adult animals, resulting in
complete amelioration of the extended clotting times in HB mice. We observe an
approximately 5-fold increase in hF.IX expression compared with our previous study in
mice treated as neonates, which could be due to the loss of AAV vector genomes during
neonatal liver development and/or differential promoter activity in each group.
Alternatively, the difference could reflect increased genome editing activity in adult mice.
Importantly, we demonstrate substantial levels of genome editing in the absence of
homology arms, which may further expand the utility of this approach by: a) allowing
correction of cells unlikely to be amenable to HDR, b) increasing the effective packaging
capacity of donor vectors by obviating the need for homology arms, and c) permitting
efficient targeting without the need to design donors which incorporate patient specific
polymorphisms. Lastly, by using obligate heterodimer FokI nuclease domains we show a
marked enhancement in the specificity of ZFN action in vivo. Future directions include
determining whether the levels of hF.IX observed in this model can be achieved by
targeting endogenous loci, which may differ in chromatin status and promoter activity.
The findings presented in this study serve to demonstrate the feasibility of genome
editing in adult, non-cycling tissues as a potential approach to the treatment of a wide
range of monogenic disease
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Figure 2.1

Figure 2.1 Sche matic of hF9mut mouse mode l and targe ting strate gy.

Mouse contains the depicted knock in construct (top) at the Rosa26 locus. The ApoE
enhancer/Human alpha-1-antitrypsin promoter drives expression of a truncated human
factor 9, devoid of catalytic exons 7-8. Untreated hF9mut mice exhibit no detectable
hF.IX protein in plasma above the limit of detection (<15ng/mL). Donor vector (bottom)
contains a splice acceptor (SA) followed by corrective wild-type exons 2-8 and poly A,
flanked by arms of homology to the ZFN target site within intron 1. ZFN mediated
targeting of the donor to hF9mut intron 1 results in splicing with Exon 1 to produce a wild
type transcript.
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Figure 2.2 In vivo ge ne corre ction in adult mice re sults in stable circulating
hF.IX le ve ls and corre ction of clotting time s in he mophilic animals.

24

(A-B) Levels of hF.IX in plasma of hF9mut (A) and hF9mut/HB (B) mice following i.v.
injection at week 8 of life with 1 x 1011 v.g. AAV8-ZFN alone, 1 x 1011 v.g. AAV8-Mock
and 5 x 1011 v.g. AAV8-Donor, or 1 x 1011 v.g. AAV8-ZFN and 5 x 1011 v.g. AAV8-Donor.
The previously described (Li et al., 2011) hF9mut mouse model of human Factor IX
deficiency contains a liver specific promoter-driven human coagulation f9 cDNA devoid
of necessary catalytic exons 7-8 knocked into the Rosa26 locus. (C) Measurement of
clot formation by activated partial thromboplastin time (aPTT) prior to, two weeks, and 80
weeks after AAV administration. The aPTT of wild-type mice is shown for comparison. A
two-tailed Mann-Whitney test was used to compare two groups. n.s., non-significant. (D)
Levels of hF.IX in treated mice remain stable following 2/3 Partial Hepatectomy (PHx).
(E) hFIX expression is over 10-fold greater following AAV8-ZFN and AAV8-Donor
treatment in hF9mut mice harboring the ZFN target site (hF9mut) compared with
littermate controls that do not (wild type). (F) PCR analysis showing successful gene
targeting by both HDR and NHEJ 5 months after i.v. co-injection of ZFN and Donor
vectors. PCR products were resolved by 5% PAGE and autoradiographed. See
Supplementary Figure 2 for maps. Mice treated with ZFN alone or with Mock and Donor
showed no evidence of targeting. Identity of the PCR products was confirmed by
sequencing.

Lower band appears in all donor treated samples, which is an artifact

apparently generated by the reverse primer and the AAV-ITR resulting in amplification
from non-integrated AAV genomes. hF.IX plasma levels were assayed by ELISA and
represent repeated measurements, obtained by serial bleeding, on the same group of
animals over the time of the study. n=number of mice in each cohort. Error bars denote
s.e.m. Plasma hF.IX data are representative of at least two independent experiments.
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Figure 2.3

Figure 2.3 In vivo ge nome e diting re duce d in olde r mice .

Levels of hF.IX in plasma of hF9mut mice following i.v. injection at either week 8 or week
30 of life with 1 x 1011 v.g. AAV8-ZFN and 5 x 1011 v.g. AAV8-Donor. A two-tailed MannWhitney test was used to compare two groups. * p<0.05
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Figure 2.4

Figure 2.4 Live r-spe cific hF9 mRNA e xpre ssion following ZFN-me diate d ge ne
targe ting.

Total RNA was isolated from tissues, reverse-transcribed and analyzed by PCR. F9
forward primer anneals to Exon 1 within the hF9mut genomic locus while F9 reverse
primer lands in Exon 8 in the AAV Donor. A unique band corresponding to site-specific
genome editing and rescue of wild type factor IX transcript was detected only in livers of
mice treated with ZFN and Donor vectors.
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Figure 2.5

Figure 2.5 Minimal le ve ls of live r ce ll prolife ration in adult mice .

Two days after administration of either saline or 1e11 vg of AAV-Mock (Luciferase), 1e11
vg of AAV-ZFNWT or 1e11 vg of AAV-ZFNELD:KKR, animals were sacrificed and
immunostaining for the proliferation marker Ki67 was used to identify replicating liver
cells. As a comparison, percentage of Ki67+ nuclei in uninjected and hydrodynamicallyinjected mice is shown. * p<0.05 vs. Untreated.
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Figure 2.6

Figure 2.6 Targe te d inte gration of the corre ctive hF9 partial cDNA casse tte .

Genotyping using primers P1 and P5 allow the detection of integration events occurring
via homology-directed repair or end-capture of the AAV donor genome at the ZFN
cleavage site.
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Figure 2.7

Figure 2.7 Homology arms in the donor ve ctor are not re quire d to achie ve
robust le ve ls of ge nome e diting.

(A) Levels of hF.IX in plasma of hF9mut and wild type mice following i.v. injection at
week 8 of life with 1 x 1011 v.g of AAV8-ZFN and 5 x 1011 v.g. of either AAV8-Donor
containing arms of homology to the ZFN target site (human F9 intron 1) or AAV8-Donor
containing arms without substantial homology†. (B) Levels of hF.IX in plasma of hF9mut
mice following i.v. injection at week 8 of life with 1 x 1011 v.g of AAV8-ZFN and 5 x 1011
v.g. of either AAV8-Donor containing arms of homology to the ZFN target site or AAV8Donor with “irrelevant” arms‡ with homology to mouse albumin intron 1. The F9 coding
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sequence (identical in all 3 donor vectors) was modified and synthesized by GeneArt,
optimizing codon usage, G/C content, secondary structures, alternative open reading
frames, and cryptic splice sites. † Derived from canine F9 intron 1: Left arm, <5%
homology; right arm, <70% homology. ‡ Both arms have less than 5% homology to the
ZFN target locus.
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Figure 2!
Figure 2.8
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Figure 2.8 Obligate he te rodime r ZFNs re duce off-targe t cle avage in vivo while
pre se rving e quivale nt le ve ls of hF.IX se cre tion.

(A) Cel-I cleavage at the 4 validated off targets identified by clustered integration site
analysis 4 weeks after treatment with 5 x 1011 v.g. AAV8-Donor and either 1 x 1011 v.g.
AAV8-ZFNWT, 1 x 1011 v.g. AAV8-ZFNELD:KKR or 1 x 1011 v.g AAV8-Mock. (B) Plasma
hF.IX levels following treatment. (C) On-target cleavage measured by Cel-I assay 4
weeks after AAV injection. (D) hF.IX expression in wild type mice lacking ZFN target site
5 weeks after injection of 5 x 1011 v.g. AAV8-Donor and either 1 x 1011 v.g. AAV8-ZFNWT
or 1 x 1011 v.g. AAV8-ZFNELD:KKR. hF.IX plasma levels were assayed by ELISA. Twotailed t-test was used. *** p<0.0001 compared with ZFNWT. n=number of mice in each
cohort. Error bars denote s.e.m. Frequency of ZFN-induced insertions and deletions is
indicated as ‘% of Indels’ below each lane. Each lane represents an individual mouse.
Plasma hF.IX data are representative of at least two independent experiments.
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Figure 2.9

Figure 2.9 Putative me chanism of hF.IX e xpre ssion in WT mice .

Detectable hF.IX in wild type mice may result from donor integration into one of the
predominant off-target cleavage sites in mouse chromosome 2. The integration site is
located in the first intron of a gene encoding FATP-2 (Fatty acid transport protein 2),
which is expressed in liver and is predicted to splice in frame with the donor cDNA. Exon
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1 of FATP-2, a transmembrane protein, could provide a signal peptide upon splicing with
the hF9 Exon 2-8 donor, supporting some secretion of the fusion protein. We quantified
this “fusion transcript” in mice treated with the wild type ZFN at a frequency ~17x higher
than in mice treated with identical doses of the obligate heterodimer. These data are
consistent with results shown in Figure 2.8A (chr2 panel).
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Figure 2.10

Figure 2.10 Comparison of alanine aminotransfe rase in mice tre ate d with
WT
ELD:KKR
Mock, ZFN
and ZFN
.

Plasma ALT values following treatment did not deviate from normal range (shaded area)
in any of the groups. ALT levels 24 hours following hydrodynamic tail vein (HTV)
injection are shown for comparison (right panel).
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CHAPTER 3: IN VIVO GENOME EDITING OF THE MURINE ALBUMIN LOCUS AS A PLATFORM
FOR PROTEIN REPLACEMENT THERAPY

This work is currently under review for publication.

37

Summary
Site specific editing of the genome is a promising approach to achieving longterm, stable therapeutic gene expression. This has been successfully applied in a variety
of preclinical models, generally focused on targeting of the diseased locus itself;
however, limited targeting efficiency or insufficient expression from the endogenous
promoter may impede the translation of these approaches, particularly if the desired
editing event does not confer a selective growth advantage. Here we report a general
strategy for liver-directed protein replacement therapies that addresses these issues:
Zinc Finger Nuclease (ZFN)-mediated site-specific integration of therapeutic transgenes
within the albumin gene. Employing adeno-associated viral vector (AAV) delivery in vivo,
we achieved long-term expression of human factors VIII and IX (hF.VIII and hF.IX) in
mouse models of hemophilia A and B at therapeutic levels. Using the same targeting
reagents in wild type mice, we expressed lysosomal enzymes that are deficient in Fabry
and Gaucher diseases, as well as in Hurler and Hunter syndromes. The establishment of
a universal nuclease-based platform for secreted protein production would represent a
critical advance in the development of safe, permanent, and functional cures for diverse
genetic and non-genetic diseases.
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Introduction
Adeno-associated viral (AAV) vectors are showing great promise in clinical trials
to deliver therapeutic genes for treatment of monogenic disorders (Bennett et al., 2012;
Nathwani et al., 2014). For gene delivery to the liver, the standard approach is to deliver
an expression cassette that persists primarily in the form of extra-chromosomal
episomes. Episomal expression faces two major limitations: (1) dilution of expression in
proliferating cells, and (2) restricted packaging capacity of the AAV vector. Site-specific
integration of a corrective donor cassette allows therapeutic gene expression to persist
through cell divisions, and increases the effective carrying capacity of the vector by
obviating the need for enhancer/promoter elements within the corrective donor.
Genome editing has been successfully applied in a variety of preclinical models,
both ex vivo and in vivo (Genovese et al., 2014; Li et al., 2011; Lombardo et al., 2007;
Perez et al., 2008; Yin et al., 2014). Historically, the efficiency of gene specific editing in
mammalian cells has been very low, limiting its therapeutic potential. The targeting
process is known to be greatly enhanced (100-1000 fold) by the induction of a DNA
double strand break at the target site (Porteus et al., 2003; Rouet, Smih, & Jasin,
1994b). The development of customized DNA cleaving enzymes, such as ZFNs, has
made it possible to achieve far greater genome editing efficiencies. ZFNs function as
dimers by coupling DNA binding motifs from transcription factors with the FokI
endonuclease domain to generate double stand breaks at their target site.
A typical genome editing approach is to target the disease locus itself; however,
the proportion of alleles targeted may not express sufficient levels of protein to alleviate
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the disease phenotype. Alternatively, integration into a locus with high transcriptional
activity (“safe harbor”) would address this limitation and provide a versatile platform to
express various proteins, substituting the donor for each respective therapeutic
transgene.
For our studies, the albumin locus was chosen as the genomic harbor due to its
very high expression level and the tractability of liver for gene delivery and in vivo
editing, relative to other tissues. In addition, the albumin gene structure is well suited for
transgene targeting into intronic sequences as its first exon encodes a secretory peptide
that is cleaved from the final protein product. By analogy to our previous work on hF9
(Anguela et al., 2013; Li et al., 2011), we reasoned that integration of a promoterless
cassette bearing a splice acceptor and therapeutic transgene would support expression
and secretion of many different proteins, as signal peptides are often functionally
interchangeable (Gierasch, 1989; Tan, Ho, & Ding, 2002).
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Materials and Methods

Animal experiments
AAV vector was diluted to 200 µl with PBS + 0.001% Pluronic F68 before tail-vein
injection. Plasma for hF.IX ELISA was obtained by retro-orbital bleeding into heparinized
capillary tubes. Plasma for aPTT was obtained by tail bleeding, 9:1 into 3.8% sodium
citrate. Tissue for nucleic acid analysis was immediately frozen on dry ice after necropsy.
Wild type C57BL6 mice were purchased from the Jackson Laboratory. Hemophilia B and
Hemophilia A/CD4 null mice have been previously described (Anguela et al., 2013; Siner
et al., 2013). Minimum sample sizes were determined by estimating mean values and
standard deviations based on previous in vivo ZFN studies, using an alpha value of .05
and a power of .80. Randomization and blinding were not conducted.
ZFN reagents and targeting vectors
Heterodimeric ZFNs targeting the mAlb locus contain the ELD:KKR mutations to
the FokI domain (Doyon et al., 2011). The promoter-less hF9 donor vector, containing a
cDNA cassette with exons 2-8 of the hF9 gene, has been previously described (Anguela
et al., 2013). All the hF8 donors carry a splice acceptor sequence derived from the hF9
gene followed by a B-domain-deleted F8 cDNA (devoid of the first 57 nucleotides
encoding the signal peptide). hF8 Donor 1 contains the SQ amino acid sequence(Lind et
al., 1995) and was codon optimized by DNA2.0. hF8 Donor 2 was codon optimized and
contains a putative glycosylation sequence and a shorter polyA sequence as described
(McIntosh et al., 2013) (summarized in Figure 3.5A). hF9 and hF8 donors do not contain
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arms of homology to the target site. The donors used in Figure 3 carry a hF9 splice
acceptor sequence followed by the cDNA encoding for α-galactosidase A, acid βglucosidase, α-L-iduronidase and iduronate-2-sulfatase, respectively. These donors
contain arms of homology of approximately 600bp to the mouse albumin target site.
AAV8 vectors were produced and titered as previously described (Ayuso et al., 2009;
Wright & Zelenaia, 2011). Sequences of mAlb-targeted ZFNs are provided in Figure
3.10.
Factor IX antigen and activity
Human factor IX ELISA kit (Affinity Biologicals) was used to quantify plasma
hF.IX. All readings below the last value of the standard curve (15 ng/ml) were arbitrarily
given the value of 15 ng/ml. hF.IX activity levels in citrated mouse plasma were
determined using chromogenic assay (Aniara, A221802).
hF.VIII activity and aPTT assay
Coagulant activity of hF.VIII in citrated mouse plasma was determined by Coatest
SP4 F.VIII (Chromogenix). The aPTT assay was performed by mixing sample plasma
1:1:1 with pooled hemophilia B (Figure 3.1F) or Hemophilia A (Figure 3.7B) human
plasma (George King Biomedical, Inc) and aPTT reagent (Trinity Biotech), followed by a
180s incubation period at 37°C. Coagulation was initiated after the addition of 25 mM
calcium chloride. Time to clot formation was measured using a STart 4 coagulation
instrument (Diagnostica Stago).
Western blot analysis of liver homogenates
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Western blot detection from liver homogenates was carried out thirty days after
treatment. Highly abundant proteins (albumin and IgG) were depleted from liver
homogenates in RIPA buffer. Primary antibodies: IDUA (MAB4119, R&D Systems,
1:1000), IDS (MAB2449, R&D Systems, 1:500), GLA (12078-R001, Sino Biological,
1:1000), GBA (sc-100544, Santa Cruz, 1:500). Secondary antibodies were from Santa
Cruz (Mouse, sc-2005; Rabbit, sc-2004).
Surveyor nuclease (Cel-I) assay
Genomic DNA from mouse liver was isolated using the MasterPure complete
DNA purification kit (Epicentre Biotechnologies) and the assay was performed as
described previously (Doyon et al., 2011; Li et al., 2011). Loci were amplified for 30
cycles (60 °C annealing and 30" elongation at 68 °C). The following primers were used
to detect DNA cleavage at the albumin locus: (5' CCT GCT CGA CCA TGC TAT ACT 3'
and 5' CAG GCC TTT GAA ATG TTG TT 3').
RT-PCR and quantitative PCR
Reverse transcription followed by qPCR was performed using Ambion’s High
Capacity RNA-to-cDNA and Fast SYBR Green Master Mix (Applied Biosystems)
according to manufacturers’ instructions. The following primers were used: mAlb Fw1 (5’
tgggtaacctttctcctcctc 3’) with mAlb Rv (5’ gggaaaaggcaatcaggact 3’) and mAlb Fw2 (5’
gtctccggctctgctttttc 3’) with hF9 Rv (5’ caggattttgttggcgtttt 3’). Cycling conditions were: 95
°C for 2 min, followed by 40 cycles of 95 °C for 15 s, 60 °C for 30 s. The delta-delta-Ct
method (2-ΔΔCt) described by Livak (Livak & Schmittgen, 2001) was used to relatively
quantitate the expression of the transcripts of interest.
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In vitro AAV transduction of primary human hepatocytes
48-well cell culture dishes (Lifetech, CM1048) were either purchased pre-coated,
or plates

(VWR, 3548) were coated with a mixture of 250 µl BD Matrigel (BD

Biosciences) in 10 ml hepatocytes basal medium (HBM from Lonza, CC-3199) (150 µl
per well). Plates were incubated for 1 hour at 37°. Thawing/plating media was prepared
by combining 18 ml InVitroGRO CP medium (BioreclamationIVT) and 400 µl Torpedo
antibiotic mix (Celsis In Vitro Technologies). Once the plates were prepared, the female
plateable human hepatocytes, (lot# AKB cat# F00995-P) were transferred from the liquid
nitrogen vapor phase directly into the 37° water bath. The vial was stirred gently until the
cells were completely thawed. The cells were transferred directly into a 50 ml conical
tube containing 5 ml of pre-warmed thawing/plating medium. To transfer cells
completely, the vial was washed with 1 ml of thawing/plating medium. The cells were
resuspended by gently swirling the tube. A small aliquot (20 µl) was removed to perform
a cell count and to determine cell viability using trypan blue solution, 1:5 (Cellgro, 25900-C1). The cells were then centrifuged at 75 x g for 5 minutes. The supernatant was
decanted completely and the cells were resuspended at 1x106 cells/ml. The matrigel
mixture was aspirated from the wells and cells were seeded at 2x105 cells/well in a 48
well dish.

Cells were then incubated in 37°C/5% CO2 incubator. At the time of

transduction, cells were switched to maintenance medium HCM (HBM from Lonza, CC3199 and HCM SingleQuots, CC-4182). AAV6 particles were diluted in HCM medium
and added to cells at indicated MOI. Transfection of mALB ZFN mRNA was carried with
Lipofectamine RNAiMAX (Lifetech). After 24h the medium was replaced by fresh HCM
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medium, which was done daily to ensure maximal health of the primary hepatocyte
cultures. For experiments where hF.IX detection by ELISA was required, the medium
sometimes was not exchanged for several days to accumulate hF.IX in the supernatants.
Indel detection using next-generation sequencing
Loci were PCR amplified from genomic DNA, and the levels of modification
determined by paired-end deep sequencing on an Illumina MiSeq. Paired sequences
were

merged

via

SeqPrep

(John

St.

John,

https://github.com/jstjohn/SeqPrep,

unpublished). Merged FASTQ reads were filtered on the following criteria: quality score
>= 15 at all positions; the 5’ and 3’ terminal 23bp must match the expected amplicon
exactly; the read must not map to a different locus in the target genome as determined
by Bowtie2 with default settings (Langmead and Salzberg, Nat Methods. 2012 Mar 4;
9(4): 357–359); deletions must be <70% of the amplicon size or <70bp long. Filtered
sequences are then aligned to the expected sequence using the Needleman-Wunsch
algorithm with penalties set to prioritize single insertions or deletions. Contiguous gaps
in either the target or query alignment were counted as indels. PCR primers for mouse
Albumin locus (adapter regions are bracketed):
mALB-MQ-I1-Fwd3
5’ [ACACGACGCTCTTCCGATCT] NNNN GTT TGA ATG CAC AGA TAT AAA CAC 3’
mALB-MQ-I1-Back3
5’ [GACGTGTGCTCTTCCGATCT] NNNN GTA ATA TGC TGC TTT TTG TTC TTC 3’
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For the analysis of off target activity, genomic DNA was isolated from mouse liver
30 days after transduction with mALB ZFNS and GBA donor (Figure 3.8D, animal 22) or
from control mouse injected with formulation buffer. ZFN activity was determined by
deep sequencing at either on-target (mouse Albumin) or off-target (Rank 1-40 off-target
sites as predicted by SELEX profile of mALB ZFNs) sites for both the PBS control and
the ZFN + Donor treated animal. Loci were PCR amplified from genomic DNA, and the
levels of modification determined by paired-end deep sequencing on an Illumina MiSeq,
as described above. To control for sequence-specific MiSeq and PCR-induced indels,
control samples were compared to treated samples. Control sample alignments were
visually inspected to ensure no treated sample PCR contamination was present. All
indels encountered in an alignment were considered when binning the read into an indel
type if more than one was present. Indel types shared between control and treated
samples were excluded from further analysis. After removal of indel types, the statistical
test described in Pattanayak et al. (Nature Methods 2011) was applied to the number of
sequences scored as indels and the total number of sequences for both the ZFN treated
sample and the cognate control (Pattanayak, Ramirez, Joung, & Liu, 2011). Loci with pvalues < 0.05 (adjusted for multiple comparisons with a Bonferroni correction) were
considered significant.
Statistics
Graphpad Prism was used to perform all statistical tests. For comparisons with
groups in which values were unmeasurable (below limit of detection), a two-sided
Fisher’s exact test was used. If data passed the D’Agostino & Pearson normality test, a
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two-sided t-test was used. Otherwise, the nonparametric Mann-Whitney test (two-tailed)
was used. In all tests, p<0.05 was considered significant.
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Results
As an initial test of the feasibility of the strategy outlined in Figure 3.1A, we
transduced human primary hepatocytes with an AAV6 vector containing the human
factor 9 (hF9) donor sequence together with transfection of mRNA encoding a ZFN pair
targeting a site within the first intron of human albumin. Hepatocytes treated with donor
and ZFNs exhibited measurable hF.IX in the culture supernatant (Figure 3.2).
We next sought to demonstrate this approach in vivo in the mouse. To
accomplish this, we first engineered a ZFN pair targeting an analogous site in mouse
albumin (mAlb) intron 1 and confirmed its activity in vitro in murine hepatoma cells
(Figure 3.3A). Next, we assessed activity in vivo via tail vein injection of eight-week-old,
C57BL/6 mice with 1x1011 vg of an AAV8 vector encoding the ZFN pair (AAV8-ZFN)
followed by Cel-I assay of the target albumin locus from liver genomic DNA, seven days
post vector administration. We observed cleavage at frequencies ranging from 12% to
17% (Figure 3.1B), indicative of small insertions and deletions (indels) characteristic of
break repair by non-homologous end-joining (NHEJ). This result demonstrated that
these ZFNs can efficiently cleave their endogenous target in the livers of adult mice and
established their suitability for studies of the albumin locus for therapeutic transgene
expression.
Hemophilia B represents an ideal disease for a liver-directed genome editing
strategy as modest levels of hF.IX activity (>1% of normal) can greatly ameliorate the
disease phenotype. To determine whether ZFN-mediated insertion of a hF9 therapeutic
donor could yield stable hF.IX expression, we treated wild type mice with 1x1011 vg of
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AAV8-ZFN and 5x1011 vg of AAV8-hF9-Donor, where the donor construct encoded a
promoterless hF9 cassette containing exons 2-8 of the hF9 gene flanked by a splicing
acceptor signal and a poly A sequence (Anguela et al., 2013; Li et al., 2011). Consistent
with ZFN-driven targeted integration, mice receiving the hF9 donor and the mAlbtargeted ZFNs exhibited high circulating human hF.IX levels (>3000 ng/mL; Figure
3.1C). Our protocol was well tolerated, and follow up studies revealed stable hF.IX
expression levels (>1 year; Figure 3.3B) as well as no significant alterations in levels of
serum alanine aminotransferase (Figure 3.3C) or plasma albumin (data not shown).
Although substantial levels of h.FIX were obtained, the hybrid mAlb-hF9 mRNA
represented a small fraction (0.5%) of total wild type mAlb transcript, as determined by
RT-qPCR analysis on liver-extracted RNA samples. This indicates only a small fraction
of hepatocytes need to be modified in order to achieve high levels of hF.IX in the blood
(Figure 3.3D). We also demonstrated that hF.IX levels could be adjusted by varying the
dose of AAV. At a fixed 1:5 ratio of ZFN to donor, transgene expression was proportional
to the AAV dose within a range of over 2 orders of magnitude, yielding ∼ 100 to 15000
ng/mL of hF.IX two weeks post treatment (Figure 3.1D).
Our strategy relies on splicing between albumin exon 1 and the integrated donor
and is predicted to create a hybrid mRNA, resulting in the substitution of a novel
tripeptide for the two amino terminal residues of the hF.IX pro-peptide. However, once
processed, the resulting mature polypeptide should be identical to wild type hF.IX
(Figure 3.4A). To test whether these substitutions affected enzyme function, we
assessed clotting activity in hemophilia B mice. We observed a correction of the
hemophilic phenotype in mice treated with AAV8-ZFN and AAV8-hF9-Donor as
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measured by activated partial thromboplastin time (aPTT) (Figure 3.1E, F). Using a
chromogenic activity assay, we then confirmed that the F.IX enzymatic activity in plasma
correlated with the antigen levels with a 1:1 ratio (Figure 3.4B), indicating that the
activity of the mature protein is not compromised. Collectively, these data show that
long-term corrective levels of hF.IX can be achieved following a single treatment with
ZFN and therapeutic donor vectors.
One of the main advantages of our targeting strategy is that it allows production
of any secretable protein without the need to change the ZFN reagent for each specific
disease. In order to test the generality of the approach, we pursued a similar strategy for
therapeutic expression of hF.VIII in a mouse model of hemophilia A (HA/CD4null). The
use of hemophilia A mice in a CD4null background allowed us to measure circulating
human hF.VIII without interference from neither endogenous mouse F.VIII nor the
development of inhibitors against the human exogenous protein. As the length of the
coding sequence for this gene (7kb) substantially exceeds the packaging capacity of
AAV (~4.7kb) an important aspect of these studies involved reducing the donor size to a
length approaching this threshold. Accordingly, our donor encoded a truncated hF.VIII
variant that has also been engineered for reduced size and more efficient
expression(McIntosh et al., 2013). The resulting donor is summarized in Figure 3.5
(“hF8 Donor 2”). To increase integration activity further, we also delivered ZFNs
individually using separate vectors (rather than a single vector encoding a dual
expression cassette), since in a preliminary study this yielded a >3-fold increase in ZFN
potency in vivo at equivalent vector doses (Figure 3.6). Combining these improvements
to ZFN and Donor design, injection of 5x1010 vg of each individual AAV8-mAlb-ZFN and
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1x1011 vg of AAV8-hF8-Donor 2 resulted in hF.VIII activity levels of 37 ± 5.5% of normal
(Figure 3.7A). Of note, the wild type F.VIII protein does not contain a propeptide
whereas the predicted hybrid mAlb-FVIII fusion will contain the murine albumin
propeptide at the N-terminus. In order to demonstrate full functionality of the mature
hF.VIII protein in vivo, we performed an aPTT assay in mice treated with AAV8-hF8Donor 2 and either AAV8-ZFN or AAV8-Mock vectors. Importantly, the observed hF.VIII
levels were able to correct the aPTT in treated hemophilia A animals (Figure 3.7B),
demonstrating that in vivo genome editing targeting the albumin locus is able to restore
hemostasis in mouse models of both hemophilia A and B.
Liver-directed gene transfer is attractive for the treatment of lysosomal storage
diseases due to the liver’s ability to secrete large amounts of protein into the blood and
the ability of many lysosomal enzymes to be taken up by cells in the periphery (“cross
correction (Fratantoni, Hall, & Neufeld, 1968).” It is anticipated that treatment of these
progressive diseases as early as possible will provide the greatest therapeutic benefits.
However, long term expression following conventional, predominantly non-integrating,
AAV administration in young patients may be compromised due to episomal dilution as
hepatocytes divide (L. Wang, Wang, Bell, McMenamin, & Wilson, 2012). Integration of a
donor into the albumin locus could potentially address this limitation. We treated adult
wild-type mice with AAV8-ZFN and four donors encoding either human α-Galactosidase
A, ß-Glucosidase, Iduronate-2 Sulfatase, or α-L-Iduronidase i.e. the genes which are
deficient in patients with Fabry, Gaucher, Hunter, and Hurler’s disease/syndromes,
respectively. Wild type mice were treated with 1x1011 vg of AAV8-ZFN and 1x1011 or
5x1011 vg of AAV8-Donor for each transgene as indicated (Figure 3.8A-D). Four weeks
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following administration, all four lysosomal enzymes were detectable by Western blot in
liver lysates of treated mice. Overall, these data provide a proof of principle
demonstrating the versatility of albumin as a targeting platform for various transgenes in
multiple species.
Finally, in order to measure ZFN off-target activity in vivo we performed deep
sequencing analysis on genomic DNA from animals treated with vehicle only or AAV8ZFN and the GBA Donor (Figure 3.8D, animal 22). We quantified rates of insertions and
deletions (indels) in the top 40 off-target sites predicted by SELEX analysis of mAlb-ZFN
binding both as homodimers and heterodimers. The on-target activity of the ZFN pair
was 31.4% whereas only 11 out of 40 potential off-target sites exhibited measurable
cleavage activity between 0.12 – 1.92% (Figure 3.9). This results in an on-target to offtarget ratio between 16:1 and 262:1. Of the 11 off-target sites, 8 were mapped to introns
of annotated genes while the other 3 sites were found in intergenic regions. While these
results illustrate the high specificity of the mAlb ZFN pair used in this study, it is
important to note that the safety evaluation of the final optimized reagents for clinical
trials should not be reduced to the absolute specificity of cleavage. As seen in clinical
trials, patterns of integration are difficult to predict from non-human genomes, and safety
concerns are highly dependent on the exact nature of the target locus and transgene
that is inserted. These reagents have only been optimized to a certain degree and
clinical application of ZFNs will undoubtedly benefit from further refinement to achieve
the highest possible safety profile.
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Discussion

Recent clinical trials using AAV-mediated gene transfer have highlighted the
tremendous potential of gene therapy (Bennett et al., 2012; Nathwani et al., 2011).
However, an unanswered question is whether episome-derived liver expression will be
sustained in a setting of substantial liver proliferation, as in pediatric patients (the liver
quadruples in size during the first 4-5 years of development (Stocker, Dehner, & Husain,
2012)) or those with liver disease (e.g. hepatitis and/or cirrhosis). For these cohorts, sitespecific integration of the transgene to avoid AAV dilution and loss of expression could
be especially beneficial. We have previously shown that in vivo genome editing can be
applied successfully with therapeutic benefit in an engineered Rosa26 locus (Anguela et
al., 2013; Li et al., 2011). Here, we demonstrate this is not a phenomenon limited to a
uniquely recombinogenic region, with insertion of a variety of transgenes into the
endogenous albumin locus of wild-type C57Bl/6 mice.
In the specific context of in vivo gene targeting, where corrected cells may not be
able to be positively selected, targeting of a limited number of cells may not result in
optimal amounts of secreted protein to correct a disease phenotype. In addition, targeted
integration of a therapeutic transgene may not be a viable solution for some diseased
loci due to mutations in the regulatory elements that control gene expression (e.g.
hemophilia B Brandenburg). The results presented here support the notion that a ZFN
pair targeting a highly expressed locus such as mouse albumin may be used to
overcome these limitations, representing an attractive platform for expression of multiple
therapeutic genes.
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Recently, it has been reported that AAV mediated targeting of the albumin locus
with no nuclease may be sufficient to correct disease (Barzel et al., 2014). We have not
observed measurable hF.IX protein in mice that did not receive a nuclease, however
these differences may be attributable to differences in our systems. The first is that our
donors do not contain the full hF.IX open reading frame, but rather exons 2-8 preceded
by a splice acceptor, rendering it extremely unlikely to produce mature protein as a result
of basal promoter activity from the AAV inverted terminal repeats or cryptic promoter
sequences in the targeting construct. In addition, the length of homology arms and
precise region of albumin targeted in the two studies were different. Nonetheless, based
on our results as well as the genome editing literature, we would predict that adding a
nuclease to this strategy would substantially improve the efficiency. This is an important
consideration as it is well known that mouse liver transduction with AAV is particularly
efficient compared to large animals (~50-100x greater at equivalent vg/kg doses). An
unanswered question is whether genome editing, in the absence of the nuclease, would
be efficient enough to elicit robust levels of protein production in large animal models
that have been shown to better predict human therapeutic doses. We believe it is
reasonable to expect that adding a nuclease would allow us to use considerably lower
AAV doses while retaining similar levels of expression to those seen by Barzel and
colleagues. With regard to safety, the critical question will be whether a high dose of
donor vector alone, which presumably relies on spontaneous DNA damage to initiate
targeting, is preferred over a potentially lower dose of donor and nuclease. In addition,
strategies based on non homologous end joining will require a nuclease and are a
promising approach for diseases such a hemophilia A, in which the transgene, even
without flanking arms of homology, pushes the limits of AAV packaging.
54

Cleavage specificity of designer nucleases remains an area of active inquiry. It is
clear that patterns of unintended cleavage depend on the specific enzyme employed,
target tissue (and species of genome), and magnitude/duration of nuclease expression.
Additionally, some of the challenges for successful clinical application of genome editing
are related to the currently available technology for nuclease delivery. An optimal vector
would permit short-lived nuclease expression in a large majority of target cells, mediating
donor integration through DNA break-repair mechanisms while minimizing risk of offtarget effects. In the proof of concept study presented here, we utilized adenoassociated viral vectors for nuclease and donor delivery to achieve efficient hepatocyte
transduction. While AAV vectors are well fit for donor delivery they may not be ideal for
nuclease expression. Nonetheless, characterization of a single, universal reagent as
opposed to multiple enzymes represents a critical advance for maximizing the safety
profile of gene editing technologies.
In summary, our results demonstrate phenotypic correction of mouse models of
two disorders, hemophilia A and B, following the administration of AAV vectors encoding
a donor construct and a ZFN pair targeting the albumin locus. This strategy can be
extended to multiple indications beyond hemophilia, with the potential for use in diverse
protein replacement therapies. In vivo experiments in large animal models are warranted
to establish a basis for clinical translation of this technology to treat a range of
monogenic diseases.
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Figure 3.1

Figure 3.1 He patic ge ne targe ting of the mouse albumin locus re sults in
phe notypic corre ction of he mophilia B.
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(A) Schematic illustrating albumin targeting strategy. (B) Cel-I nuclease assay from liver
DNA measuring ZFN-induced indels within albumin intron 1. Lanes represent individual
mice at day 7 post AAV8-mALB-ZFN treatment. (C) hF.IX in mouse plasma following
treatment with AAV8-hF9-Donor and either AAV8-mALB-ZFN (●) or AAV8-hF9-ZFN (♦,
with a target sequence not present in the mouse genome). n=3 mice per group (D) hF.IX
levels at week 2 post-treatment are proportional to AAV dose (1:5 ZFN to Donor). Grey
line: normal levels. Points represent individual mice. (E) hF.IX levels in hemophilia B
mice two weeks after treatment with AAV8-mALB-ZFN and AAV8-hF9-Donor. n=4 mice
per group. *p=0.029, Fisher’s exact test (F) Clot formation in mice (panel E) measured
by aPTT prior to and 2 weeks after treatment. The aPTTs of wild-type mice are shown
for comparison. **P<0.01, 2-tailed Mann-Whitney test. n.s. = non-significant.
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Figure 3.2

Figure 3.2 ZFN me diate d targe ting of the albumin locus in primary human
he patocyte s.

Human primary hepatocytes were transduced in vitro with AAV6 hF9 donor (MOI 9x105
vg/cell) and 24h later with 500ng of mRNA encoding albumin-targeted ZFNs. Bottom
panel: % of albumin sequences with insertions and deletions (indels) as measured by
MiSeq analysis. Supernatants taken at Day 5, 7 and 9 were analyzed for hF.IX levels by
ELISA. Error bars = s.e.m. Data are representative of at least 2 independent
experiments.
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Figure 3.3

Figure 3.3 Characte rization of mAlb-targe te d ZFNs in vitro and in vivo.

(A) ZFN activity measured by indels in Hepa 1-6 cells transfected with indicated amount
of ZFN or GFP mRNA. Genomic DNA was isolated and the target sequence was PCR
amplified for Illumina MiSeq sequencing. Percentages indicate reads containing indels
consistent with cleavage and NHEJ repair. (see Methods) (B) Levels of hF.IX in treated
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mice remained stable for more than a year following IV injection with 5x1011 vg AAV8hF9-Donor and 1x1011 vg AAV8-ZFN. (C) Plasma ALT values following treatment did
not deviate from normal range (shaded area). (D) Quantitative PCR was used to
determine the relative abundance of hybrid mAlb-hF9 mRNA vs. wild type mAlb mRNA
(transcripts and priming scheme indicated schematically at top). Mice were injected with
1:1 ratio of ZFN:Donor at indicated doses. Total RNA was isolated from livers of mice 2
weeks post injection. As a negative control, Luciferase (Mock) + Donor was given at the
higher dose of 5x1011 vg each. A 2-tailed Mann-Whitney test was used to compare 2
groups. n=6-8 mice/group. Error bars = s.e.m.
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Figure 3.4

Figure 3.4 hF.IX activity is not affe cte d by the N-te rminal modification
re sulting from donor splicing with albumin e xon 1.

(A) Schematic showing the wild type propeptide of hF.IX (top) and the expected
propeptide resulting from the splicing event between mouse albumin exon 1 and the hF9
donor (below). (B) Hemophilia B mice were injected with 1x1011 vg of AAV8-ZFN and
5x1011 vg of AAV8-hF9-Donor. Twenty weeks post-injection, the biological activity of
hF.IX was measured using a chromogenic assay and antigen levels were determined by
ELISA. A 2-tailed Mann-Whitney test was used to compare 2 groups. There was no
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significant difference in the hF.IX levels measured by these two assays. n=3 mice. Error
bars=s.e.m. No activity or antigen were detected in uninjected mice.
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Figure 3.5

Figure 3.5 Donors use d for hF.VIII studie s.

Upper: Table summarizing donor features. Lower: Donor sketches highlighting key
regions.
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Figure 3.6

Figure 3.6 Individual ZFNs

Top: Bicistronic vector utilizing ribosomal skipping “2A” peptide for ZFN-Left and ZFNRight expression. Middle: Individual ZFN vectors each encoding a single ZFN. Bottom
graph: Indels at ZFN target site measured by Illumina MiSeq from livers of mice injected
with indicated AAV dose at week 2 post treatment. Each point represents an individual
mouse. Note that this study used the “hF8 Donor 1” from Figure 3.5.
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Figure 3.7

Figure 3.7 Targe ting of albumin supports production of the rape utic le ve ls of
Factor VIII and functional corre ction of he mophilia A phe notype .

(A) F.VIII activity as determined by chromogenic assay in hemophilia A/CD4 deficient
mice 2 and 8 weeks after treatment with 1x1011 vg of AAV8-Mock (●) 5x1010 vg of each
individual AAV8-mAlb-ZFN (●) and 1x1011 vg of Donor 2 (see Methods for details).
*p=0.08, Fisher’s exact test. (B) Measurement of clot formation by activated partial
thromboplastin time (aPTT) prior to, and 11 weeks after AAV administration. The aPTT
of WT (■) and Untreated (●) mice are shown for comparison. A 2-tailed Mann-Whitney
test was used to compare the 2 groups.
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Figure 3.8

Figure 3.8 Expre ssion of lysosomal e nzyme s de ficie nt in Fabry and Gauche r
dise ase s, as we ll as in Hurle r and Hunte r syndrome s.

Upper panels: Western blot detection of α-Galactosidase A, ß-Glucosidase, Iduronate-2
Sulfatase and α-L-Iduronidase in liver lysates of mice 30 days following treatment with
1x1011 vg of AAV8-mAlb-ZFN and 1x1011 vg of AAV8-of the appropriate donor (see
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Methods for details). Middle panels: PCR detection of bands consistent with homology
directed (HDR) and homology independent (NHEJ) integration of donor at the albumin
locus. Lower panel: Indel formation as measured by MiSeq sequencing. n=3 mice per
group. Each lane represents an individual mouse.

67

Figure 3.9

Figure 3.9. mALB ZFN off-targe t activity.
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Figure 3.10

Figure 3.10 Amino acid se que nce s of ZFNs use d to targe t intron 1 of mAlb

(A) ZFNLeft and (B) ZFNRight amino acid sequences used in the study. 3xFLAG tag is
annotated in blue. The SV40 large T antigen nuclear localization sequence is annotated
in green. FokI domain is annotated in red.
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CHAPTER 4: MECHANISMS OF GENOME EDITING OF THE MURINE LIVER

The data in chapter 4 are preliminary and unpublished
Figures 4.1/4.2 were partially represented in chapter 2 (Figure 2.2F and 2.7A)
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Summary
Genome editing has the potential to provide long-term therapeutic gene
expression in vivo. We have previously demonstrated efficient editing in a mouse model
of hemophilia B through liver-directed adeno-associated viral vector (AAV) delivery of a
zinc finger nuclease (ZFN) pair and a corrective donor. As a consequence of a splice
acceptor contained in the donor, both HDR and homology independent vector integration
are capable of driving human factor 9 (hF.IX) expression, however, the relative
contributions of each pathway is not known. In the work outlined in this chapter we
sought to better understand the molecular requirements of in vivo genome editing in both
adult and neonatal mice. Insights from these investigations allowed us to demonstrate
two possible strategies to bias repair choice in the direction of HDR, with the potential to
improve both the efficacy and safety of therapeutic gene targeting.
To address this question we designed a novel donor designed to report NHEJ
and HDR repair by expressing one of two differentiable surface markers depending on
the molecular outcome of the integration event. In neonatal mice, we observed
predominantly expression consistent with HDR repair. Importantly, we were able to
enrich for these cells in order to perform a southern blot, observing a band consistent
with HDR in the enriched hepatocytes. In adult mice, reporter expression consistent with
HDR appeared to be lower than in neonates, however the results were inconclusive,
apparently due to high background expression from the excess of non-integrated
episomal vectors.
Returning to hF.IX as our primary readout of genome editing, we compared
expression levels in mice treated as neonates and as adults with equivalent AAV doses
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and routes of administration using vectors with and without arms of homology. In mice
treated as neonates, we observed significantly higher hF.IX expression 10 weeks post
injection when using homologous donors. In contrast, mice treated as adults with the
same vectors did not exhibit differences in expression with respect to donor homology.
We repeated these experiments in mice with impaired NHEJ function (Prkdcscid/scid), and
observed a 95% reduction in homology independent targeting with no reduction in HDR.
Finally, we asked whether HDR could be stimulated more specifically through the
induction of DNA single strand breaks (“nicks”) at the target site. We treated neonatal
mice with homologous or non-homologous donors, as well as ZFNs or ZFNickases
(which create DNA nicks rather than double strand breaks). ZFNickases induce robust
genome editing with a far greater bias towards HDR than ZFNs. These data suggest
ZFNickase treatment of neonatal mice could achieve therapeutic protein production with
minimal integration at unintended sites.
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Introduction

DNA double-strand breaks (DSBs), left unrepaired, are among the most
catastrophic threats to a cell’s viability, likely resulting in the loss of genetic information
once the cell divides. Over the last few decades, research has revealed a great deal
about the many cellular responses that have evolved to deal with DNA damage. In
eukaryotes, two general pathways are capable of repairing DSBs: NHEJ and HDR
(introduced in chapter 1). In higher eukaryotes, NHEJ is the more common mechanism,
active throughout the cell cycle, while HDR is thought to be restricted to dividing cells
particularly in the late S and G2 phases of the cell cycle. Both can be sub-divided due to
the existence of multiple pathways leading to similar resolutions of a DNA break.
Proteins involved in both pathways have been genetically knocked out in mice and often
result in genome instability, sensitivity to radiation, and in many cases embryonic
lethality.
The mechanism historically called NHEJ is often referred to as C-NHEJ
(classical/canonical nonhomologous end joining (Alt, Zhang, Meng, Guo, & Schwer,
2013; H. Wang et al., 2003)). Ku70 and Ku80 are C-NHEJ factors that recognize DSBs
as a heterodimer. These two proteins, together with DNA-PKcs (catalytic subunit of the
DNA protein kinase complex) are able to activate Artemis, an endonuclease involved in
end processing. Finally, the XRCC4-Lig4 complex mediates the actual joining of the
broken DNA ends. C-NHEJ is best characterized in primary tissue in its critical function
in the development of B and T cell antigen receptors. From a relatively small amount of
genetic information encoded in the germline, millions of cells are able to generate
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remarkable diversity by independently recombining coding regions of their B-cell
receptor (immunoglobulin) or T-cell receptor genes. During this process, known as V(D)J
recombination, coding regions from different locations of a linear chromosome are cut
and ligated together (excising the intervening segment). DNA cleavage created during
V(D)J recombination results in asymmetric products: (i) covalently sealed DNA ends
(hairpins) that eventually form the immune receptor coding sequences and (ii) double
stranded ends of the fragment excised from the genome, more similar to those made by
restriction enzymes.
One of the most common immunodeficient mouse models, SCID, is the result of a
mutation in the gene encoding DNA-PKcs (Prkdc). Interestingly, Prkdcscid/scid mice exhibit
dysfunctional repair of hairpin ends (which results in the characteristic V(D)J deficiency)
but are not deficient in the repair of ends which do not require processing (Alt et al.,
2013). Although the relationship between the Prkdcscid/scid genotype and the fate of AAV
vector genomes may depend on many factors, it is possible the hairpins in the ITRs
require similar processing for NHEJ mediated integration.
Homology Directed Repair (HDR) is a key pathway by which many organisms protect
their genomic integrity. In the somatic cells of higher eukaryotes (e.g. mammals), this
pathway is less active than in other well characterized eukaryotic systems, such as
yeast. Nonetheless, mutations in many proteins involved in HDR repair result in severe
genetic diseases, highlighting the importance of this pathway in maintenance of genetic
information. Like NHEJ, many details of the HDR pathway in mammalian cells are
unknown, particularly with regard to the numerous levels of control that modulate the
various proteins and thus the final outcomes of repair.
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One of the major requirements for HDR repair of DSBs is the processing of the broken
ends to generate single stranded DNA (ssDNA). In human cells, this involves the MRN
complex of MRE11-RAD50-NBS, exonucleases EXO1 and CtIP, and the BLM helicase

(Heyer, Ehmsen, & Liu, 2010). Exposed ssDNA is quickly bound by replication protein
A, or RPA. Mediator proteins, like BRCA2 are able to substantially increase the rate that
RPA is replaced with filaments of RAD51 protein monomers, which are involved in
homology search and DNA-strand invasion, in a process called synapsis (San Filippo,
Sung, & Klein, 2008). By bringing together the damaged locus, which now has a 3’
overhang, and the template sequences for repair, a displacement loop (D-loop) can form
to allow the overhang to “invade” the template DNA and act as a primer for DNA
polymerization. This can be resolved in at least 3 different processes for which we have
direct evidence in human cells: dHJ (double Holliday junction, rare in non meitic cells),
SDSA (synthesis-dependent strand annealing, likely the most common in somatic cells),
and BIR (break-induced replication, which may result in a loss of genetic information).
Critical proteins in this process are regulated in terms of expression and posttranslational modifications in a manner that is linked to the cell cycle. These multilayered
mechanisms of control remain to be fully characterized, but in general there is strong
interaction between cell cycle and phosphorylation, ubiquitylation, and other
modifications to RPA (Fanning, Klimovich, & Nager, 2006), RAD51 (Sørensen et al.,
2005), BRCA2 (Esashi et al., 2005), and CtIP (Yu, Fu, Lai, Baer, & Chen, 2006), which
maximize activity during the S phase. This behavior is compatible with the teleological
argument that the ideal template for repair is the sister chromatid after DNA replication,
where no genetic information would be lost.
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DNA “nicks,” or single strand breaks (SSBs) are also thought to be capable of
stimulating HDR. Some of the most appropriate evidence of this for the work described in
this chapter comes from the observation that wild-type AAV integrates preferentially at a
specific site (AAVS1). Recombinant AAV integration does not display this preference,
and the Rep protein is known to induce nicks (but not DSBs) at the AAVS1 locus.
Expression of AAV Rep is able was shown to stimulate HDR using a plasmid donor at
the AAVS1 site (van Nierop, de Vries, Holkers, Vrijsen, & Gonçalves, 2009). Since then,
several groups have demonstrated the ability of nicks to stimulate HDR with potentially
less NHEJ (Davis & Maizels, 2014; Metzger, McConnell-Smith, Stoddard, & Miller, 2011;
Ramirez et al., 2012). This observation could be related to the fact that nicks are much
more common than DSBs and are typically repaired by mismatch repair mechanisms,
except during DNA replication, where an unrepaired nick could lead to replication fork
collapse. Intriguingly, this is also the ideal cell cycle state for the promotion of HDR
repair.
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Materials and Methods
Animal experiments
Animal experiments were approved by the Institutional Animal Care and Use
Committee at the Children’s Hospital of Philadelphia. Previously described heterozygous
male hF9mut (F9 ZFN, (Li et al., 2011)), wild type C57Bl/6 (Jackson laboratory), or
B6.CB17-Prkdcscid/SzJ (Jackson laboratory) mice were used. hF9mut mice were
obtained by crossing male homozygote hF9mut mice with previously described HB
females. For IV injections in adult mice, AAV vector was diluted to 200μl with PBS +
0.001% Pluronics before tail-vein injection. IP injections in neonatal mice were
performed as previously described (Li et al., 2011). For retro-orbital injections in neonatal
mice, vectors were administered according to an established protocol (Yardeni,
Eckhaus, Morris, Huizing, & Hoogstraten-Miller, 2011). Plasma for human factor IX
ELISA was obtained by retro-orbital bleeding into heparinized capillary tubes. Tissue for
nucleic acid analysis was immediately frozen on dry ice after necropsy.
ZFN reagents and targeting vectors
ZFNs targeting the hF9mut locus and F9 targeting vectors have been previously
described (Anguela et al., 2012), as well as the ELD:KKR mutations to the FokI domain
to construct the obligate heterodimeric ZFNs (Doyon et al., 2011). Experiments shown in
figures 4.10, 4.11, and 4.12 used individual ZFN vectors at the indicated total dose (1:1)
ratio as decribed in chapter 2. AAV8 vectors were produced and titered as previously
described (Ayuso et al., 2009),(Wright & Zelenaia, 2011).
Factor IX levels and activity
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Human factor IX ELISA kit (Affinity Biologicals; Ancaster, ON, Canada) was used
to quantify plasma hF.IX. All readings below the last value of the standard curve (15
ng/ml) were arbitrarily given the value of 15 ng/ml except where otherwise indicated.
Hepatocyte Isolation
Hepatocytes were isolated using a modified 2-step collagenase in situ perfusion
(Duncan et al., 2010). Briefly, anesthetized mice were immobilized on a warmed
dissecting board by rubber-bands. A ventral midline excision was made to expose the
liver and lungs, and the ribs were cut on both sides to expose the heart. A 23-gauge
butterfly needle (connected to a peristaltic pump) was inserted into the inferior cava via
the right atrium, and the portal vein was cut to allow solution to exit. The mouse was
perfused until completely blanched using warm EGTA containing solution 1, followed by
collagenase IV containing solution 2 (recipes described below). When cells were
sufficiently dissociated (roughly 5 minutes, depending on collagenase activity, liver size,
and quality of cannulation, livers were removed from mice and placed into petri dishes.
After removing the gallbladder, liver cells were mixed with 20mL solution 3 and filtered
through a 70-micron filter into a 50mL conical tube. Cells were washed twice at 30x g for
5’ to remove a majority of non-parenchymal cells, and finally subjected to an iso-density
percoll gradient as described to further separate live hepatocytes (Kreamer et al., 1986).
Flow cytometry
All antibodies were obtained from BD. CD8-APC (BD 561421) and CD4-PE (BD 561843)
staining was performed on freshly isolated 293T cells or hepatocytes by incubating in
200uL FACS buffer for 30’ at 4C. Cells were washed twice at 1500rpm/5’ (293T cells) or
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30x g/5’ (hepatocytes) before resuspension in FACS buffer for flow cytometric analysis.
Fluorescence was read using a BD FACS Canto II in the Children’s Hospital of
Philadelphia (Colket Translational Research Building, Suite 5400).
MACS Based Enrichment of CD4+ Cells
Primary hepatocytes from hF9mut mice treated with ZFN and Dual Reporter were pooled
and subjected to a second round of iso-density percoll enrichment to minimize the
numbers of dead cells present (which were found to bind magnetic beads
nonspecifically, and clogging Miltenyi LS columns used for enrichment). Staining was
performed according to manufacturers instructions using CD4-PE primary antibody and
magnetic bead conjugated anti-PE antibody (Miltenyi 130-048-801).
In Vitro Transfections
HEK 293T Cells were transfected according to manufacturers instructions with
Lipofectamine LTX. Briefly, 1μg DNA (in TE) was diluted to 100μL in OptiMEM, and
complexed with Lipofectamine LTX reagent (1μL in 100uL). Expression plasmids were
derived from PiggyBac transposon system which constitutively express GFP under
control of the PGK promoter and contain a CMV promoter driving each indicated
expression cassette. All expression cassettes contained hF9 exon 1 and a truncated 3’
coding sequence separated by hF9 intron 1. SA—2A—CD8, SA—2A—CD4, SA—2A—
CD8—(Homology)—SA—2A—CD4 were inserted within intron 1 to generate the final
expression cassettes.
Hydrodynamic Tail Vein Injections
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Wild type C57Bl/6 male mice were injected with 2μg/mg plasmid DNA in Saline with
injection volume of 10% (volume/mass) body weight. Non-signaling hCD8 and hCD4
constructs based on (Gadue, Huber, Paddison, & Keller, 2006) were synthesized by
Integrated DNA Technologies (Coralville, Iowa) and GenScript (Piscataway, NJ),
respectively. The ORFs were cloned into plasmids under control of the human alpha-1antitrypsin promoter (Manno et al., 2006).
PCR-based genotyping
Primers binding to a sequence upstream of exon 1 unique to the hF9mut mini-gene and
within a sequence unique to the donor were used to amplify targeting events from
genomic DNA. Genomic DNA from mouse liver was isolated using the MasterPure
complete DNA purification kit (Epicentre Biotechnologies; Madison, WI, USA). To detect
the targeting of the donor cassette via NHEJ or HDR, gDNA was amplified using the P1
(5'ACGGTATCGATAAGCTTGATATCGAATTCTAG3')

and

P5

(5'GCCCTTCTGGAACTGGACGAACC3') primers binding respectively to a sequence
upstream of exon 1 unique to the hF9mut mini-gene and within a sequence unique to the
donor found in exon 8 of hF9. The PCR reactions were performed using Phusion Highfidelity DNA polymerase (New England BioLabs; Ipswich, MA, USA) in conjunction with
GC Buffer and 3% dimethylsulphoxide for 25 cycles (10" denaturation at 98°C, followed
by 1'50'' of extension at 65°C). The PCR products were then purified with G50 columns,
resolved by 5% PAGE and autoradiographed.
DNA analysis by Southern Blot
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Genomic DNA was digested overnight at 37ºC with the restriction enzyme Stu I. The
next day, 6x loading dye was added to the digested genomic DNA prior to loading on a
1% agarose/TAE gel with DNA Molecular weight Marker X (Roche) as a marker.
Samples were run for 4-5 hours at 50-60 volts. Gel treatment was carried out prior to the
transfer of the DNA to the blot, consisting of 0.25N HCl (1.5 M NaCl; 0.5M NaOH) for 15
minutes to allow depurinization of DNA and mitigate the bias towards higher transfer
efficiencies of smaller fragments. The gel was next treated for 30 minutes in neutralizing
solution (1M Tris; 3 M NaCl). Blotting was carried out using positively charged nylon
membranes (Roche) and the Turboblotter system (Schleicher & Schuell, USA). This
system allows the transfer of DNA to membranes by capillary action in high ionic
strength buffer (10x SSC) through absorbent papers (GB002 and GB004, Schleicher &
Schuell, Keene, New Hampshire) for 2 hours. The blot was then irradiated with
120,000 μJ of ultraviolet light for 25-50 seconds in a UV-Stratalinker 1800 (Stratagene;
La Jolla, CA). Next, the blot was pre-hybridized for 2 hours at 65ºC in a solution
containing proteins, SDS and ssDNA to block free binding sites and reduce subsequent
non-specific binding. Hybridization was carried out overnight at 65ºC with a specific
probe (synthesized as a gBlock by IDT (Coralville, Iowa) corresponding to intron 1 within
the hF9mut construct but not the donor vector. The probe was radiolabeled using
random primers and [α-32P]-dCTP. The non-incorporated radioactive nucleotides were
separated with Sephadex G-50 gel filtration columns (Probe Quant G-50 Micro Columns,
Amersham). The hybridization was carried out overnight at 65ºC with rotational agitation.
The following morning several washes were performed, consisting of consisted of 3
consecutive washes with progressively higher stringency: two 10-minute washes at room
temperature with a low-stringency buffer solution and a final 15-minute wash at 65ºC
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with a high-stringency buffer solution. Finally, the blots were exposed to a photographic
film (Eastman KODAK Company, New York). The untargeted (unmodified) locus is
expected to yield a 5530bp band, while the on target HDR-mediated integration of CD4
is expected to yield a 1772bp band.
Hybridization solution: 0.25 mM Na2HPO4 pH 7.2; 10% W/V SDS; 1 mM EDTA; 0.5%
W/V Blocking Reagent (Roche Diagnostics).
Low astringency solution: 2x SSC; 0.1% W/V SDS
High astringency solution: 0.1x SSC; 0.1% W/V SDS

Statistics
Graphpad Prism was used to perform all the statistical tests. If data passed the
D’Agostino & Pearson normality test, then a two-sided t-test was used. Otherwise, the
nonparametric Mann-Whitney test (two-tailed) was used. In all tests, p<0.05 was
considered significant.
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Results
Based on data outlined in Chapters 2 and 3, we were aware that in vivo editing of
the liver required nuclease activity as well as the appropriate target site to be present in
the genome for production of secreted protein. Further, two experimental controls
provided strong evidence that expression was derived from integrated donor rather than
through recombination between extra-chromosomal vectors or through trans-splicing
from an endogenous transcript to the episomal donor: (i) protein was not observed in
mice treated with Mock (expressing luciferase) and Donor and (ii) expression was not
diluted as one would expect from episomes following 2/3 partial hepatectomy (as one
would expect from episomal expression).
Evidence for both NHEJ and HDR involvement in AAV donor integration
To investigate the contributions of NHEJ and HDR pathways to the observed
editing phenotype (the expected outcomes are depicted in Figure 4.1), we amplified the
targeted locus from liver genomic DNA of mice treated as adults. By designing primer
pairs to flank the integration junction (one annealing to the mouse chromosome
upstream of the ZFN target site, and the other annealing to the donor cassette), we
observed bands consistent with both repair mechanisms (Figure 4.2). Band identities
were Topo-cloned and sequence verified, suggesting both processes contribute to
functional correction in our model in adult mice. Through a similar PCR-based assay our
lab previously published evidence of both HDR and NHEJ in mice treated as neonates
((Li et al., 2011)). However, the AAV inverted terminal repeats (ITRs) possess strong
secondary structure (80% G/C content, Tm >95C), making quantitative PCR analysis
difficult due to the very low amplification efficiency of ITR-containing sequences. In
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addition, the “gold standard” method to characterize the state of DNA, Southern blot, is
not sensitive enough to detect modifications that are expected to be several orders of
magnitude less abundant than a single copy allele.
Development and evaluation of a “Dual Reporter” to distinguish between NHEJ and HDR
In order to perform a more quantitative analysis of the relative contribution of
HDR and NHEJ, we developed a novel reporter (conceptually similar to the
positive/negative selection used in ES cells to generate knock-in and knockout mice). As
outlined in Figure 4.3, the reporter (“Dual Reporter”) is intended to generate distinct
outcomes depending on whether sequences that are outside of the arms of homology
are excluded during genome editing. The human CD4 marker (in red) is flanked by arms
of homology, and thus should be expressed on the cell surface of hepatocytes that
undergo HDR mediated editing using the dual reporter. Alternatively, we would expect
the human CD8 marker (in blue) to be expressed on hepatocytes in the case of
homology independent insertion of the reporter. Extracellular surface markers were
chosen due to the availability of high quality detection reagents and their suitability for
use in downstream manipulations such as magnetic bead enrichment.
Our previous results using an hF9 donor relied on splicing of endogenous exon 1
with exons 2-8 of F9 from the donor. Since we were unsure if fusion of the hF.IX signal
peptide encoded in exon 1 would adversely affect the reporter (conformation, stability,
localization, etc…), we inserted a picornavirus “2A” sequence between the splice
acceptor (SA) and the CD8/CD4 open reading frames. Ribosome skipping caused by the
“2A” peptide should allow translation of CD8 or CD4 with only 2 additional amino acids
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rather than an extraneous F9 signal peptide. Finally, to avoid the possibility of
confounding effects due to the reporter genes themselves causing a phenotype in the
mouse liver, we employed non-signaling variants of CD8 and CD4.
We first tested the SA—2A—CD8, SA—2A—CD4, and SA—2A—CD8—
Homology—CD4 constructs by generating expression plasmids driven by the CMV
promoter and transiently transfecting HEK 293T cells. GFP was expressed constitutively
as a transfection control. By flow cytometry, we were able to detect surface expression
of both CD8 and CD4 on transfected cells (Figure 4.4A-E). Interestingly, when both CD8
and CD4 were inserted in tandem (as we would expect in the case of the entire reporter
vector integrating at the target locus), we were unable to detect CD4 expression derived
from skipping of the CD8 splice acceptor, despite the fact that expression/detection of
CD4 was more robust than CD8 (Figure 4.4F). This may reflect the strong transcription
termination activity of the bovine growth hormone poly-adenylation signal. Most
importantly, this finding simplifies the interpretation of the dual reporter, with CD8 and
CD4 expression representing NHEJ and HDR, respectively.
After determining that the SA and “2A” peptide did not interfere with expression
or detection of either surface antigen, we next asked whether these would be expressed
and detected in hepatocytes in vivo. We generated plasmids containing expression
cassettes similar to those in Figure 4.3, driven by the strong liver specific hAAT
promoter, and treated mice via hydrodynamic tail vein injection. Surface staining was
performed two days after delivery by isolating single hepatocytes via 2-step collagenase
perfusion. We observed detectable shifts in fluorescence for both reporters, confirming
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expression by hepatocytes in vivo and compatibility of CD4 and CD8 with hepatocyte
isolation procedures (Figure 4.5).
The Dual Reporter supports the notion that HDR is the predominant mechanism of
integration in neonatal mice
We treated hF9mut neonates with IP administration of 5x1010 vg AAV8ZFN/Mock and 2.5x1011 vg AAV8-Dual-Reporter (identical to the original doses
described in our earlier neonatal study(Li et al., 2011)). When sacrificed as adults,
hepatocytes isolated from the livers of mice treated with ZFN and Dual Reporter
exhibited surface staining of CD4 (consistent with HDR mediated targeting) on roughly
1.5% of hepatocytes (Figure 4.6). Mice that did not harbor the hF9mut cassette and
those that received Mock + Dual Reporter did not express measurable levels of CD4,
consistent with our observations using hF9 donors. CD8 expression appeared similar
between all groups, suggesting a less substantial contribution from NHEJ mediated
vector integration.
Magnetic bead enrichment of CD4 expressing hepatocytes yielded approximately
13-fold enrichment in CD4+ cells, from which genomic DNA was isolated. CD4 enriched
genomic DNA was pooled from two experiments, representing 10 mice in total, and
analyzed by southern blot using a radiolabeled probe which hybridized to the intronic
region within the hF9mut locus. We detected a ~1.8kb band in the CD4 enriched but not
unenriched (Neg) cells, consistent with HDR in mice treated as neonates (Figure 4.7).
Ambiguous results in adult mice treated with Dual Reporter
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In adult mice, results from the Dual Reporter were less conclusive. Mice were
treated with doses 1x1011 vg ZFN and 5x1011 vg Dual Reporter via tail vein injection,
identical to the majority of the experiments conducted with hF9 donors in order to make
the best comparisons to previous results in adult animals. The most interesting finding
was that the predominant reporter gene expressed in all groups was the opposite of
what was seen in mice treated as neonates (Figure 4.8), suggesting a greater
contribution of NHEJ in adults. There was no statistically significant difference seen in
CD8 expression between mice that harbored the ZFN target site and those that did not
(hF9mut vs. WT, Figure 4.8). As these results were not consistent with hF.IX expression
data, we hypothesize that either the signal (on target vector integration) was insufficiently
low for a meaningful measurement, or that the noise was insufficiently high (e.g.
expression of CD8 derived from ITR promoter activity, as suggested by CD8 expression
in Mock + Dual Reporter treated mice). In either case, the rate of NHEJ mediated vector
integration could not be appropriately with these tools. We did note low levels of CD4
expression in adult mice treated with ZFN + Dual Reporter, suggesting some HDR
contribution to the total hF.IX expression. Although we cannot directly compare these
results with the outcomes in neonatal mice (due to the differences in dose and route of
delivery), the relative ratios of NHEJ and HDR appear to be reversed in adult mice,
suggesting a predominant role for NHEJ in mediating targeted integration in mice treated
as adults.
Evaluation of donor vectors with and without arms of homology in adult and neonatal
mice
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An alternative approach to characterize the contributions of HDR and NHEJ is to
compare expression of hF.IX derived from donors with and without arms of homology to
the target site. Expression resulting from non-homologous donors is by definition the
result of homology independent repair, whereas expression derived from donors with
flanking arms of homology can reflect both repair mechanisms. In order to make the
most direct comparisons, we performed experiments using the same route of
administration (IV) via tail vein or retro-orbital injection for adults and neonates,
respectively. In addition, all donor hF9 cassettes contained the same codon optimized
sequences (< 85% similarity to wild-type) to avoid homology between this portion of the
cassette and the hF9mut target locus (that contains a truncated wild-type hF9 Exons 16). Mice treated as adults, with ZFNs targeting either the hF9mut knock-in locus or the
wild-type albumin locus, did not display a difference in hF.IX expression whether the
donors did or did not contain arms of homology (Figure 4.9, reproduced from chapters 2
and 3). On the other hand, mice treated as neonates, with the same AAV doses and
route of administration (IV via retro-orbital injection), exhibited substantially (6-10 fold)
more hF.IX expression when treated with donors containing arms of homology to the
target site (Figure 4.10). This difference was evident in both hF9mut mice treated with
human hF9 ZFNs and WT mice treated with mAlb ZFNs, suggesting the observation was
not a unique characteristic of the highly recombinogenic Rosa26 locus in which the
hF9mut cassette is inserted. These results demonstrate that gene targeting with ZFNs
does not require homology in adult mice, but is largely homology-dependent in neonates.
These findings are consistent with the presence of ongoing cell division in the developing
neonatal liver, during which HDR factors are expressed and activated.
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Evaluation of gene targeting in adult mice deficient in NHEJ (SCID)
We repeated these experiments in Prkdcscid/scid mice to determine if a deficiency
in NHEJ but not HDR repair would skew the observed hF.IX expression in mice treated
with homologous and non-homologous donors. Neonatal SCID mice treated with 1x1011
AAV8-mAlb-ZFN and 5x1011 AAV8-Homology-Donor exhibited high levels of hF.IX
expression, comparable to the levels observed in WT (Prkdcwt/wt) mice (Figure 4.11,
blue). In contrast, when treated with donors without homology to the albumin locus, mice
expressed substantially less hF.IX, with a mean expression of 46.5 ± 7.7 ng/mL 4 weeks
post treatment. This value is nearly 15-fold less than what was measured in Prkdcwt/wt
mice at similar timepoints. This finding supports the conclusion that DNA-PKcs promotes
AAV integration.
Gene targeting with ZFNickases to promote HDR in neonatal mice
We next asked whether HDR could be stimulated even more specifically through
the induction of DNA single strand breaks (DNA “nicks”) at the target site instead of
DSBs ((Kim et al., n.d.; Ramirez et al., 2012). As before, we treated neonatal mice with
ZFNs and homologous or non-homologous donors. In addition, we replaced the ZFNs
with ZFNickases, in which one FokI nuclease domain’s catalytic activity was inactivated
with the D450A mutation ((Sanders, Catto, Bellamy, & Halford, 2009; Waugh & Sauer,
1993)). ZFNickases were indeed active, resulting in ∼250 ng/mL hF.IX 4 weeks post
injection with homologous donor (Figure 4.12A). Interestingly, we could not detect hF.IX
in mice treated with ZFNickase and non-homologous donor (LOD: 15ng/mL). To rule out
the possibility that our inability to detect hF.IX expression in neonatal mice treated
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without homologous donors was simply due to the lower efficacy of ZFNickases
compared to ZFNs, we attempted to normalize HDR efficiency by increasing the
ZFNickase dose 4 fold. Four weeks post treatment, we observed much higher levels of
hF.IX in mice treated with 4X ZFNickase and homologous donor (2041 ± 269 ng/mL,
Figure 4.12B), but were again unable to detect hF.IX in mice treated with the non
homologous donor. Together, these data suggest neonatal hepatocytes favor HDR
pathways for genome editing, and that manipulation of the DNA damage response is
capable of further enhancing this preference. Refinements based on improved molecular
understandings of genome editing will continue to increase both the efficiency and safety
profiles of in vivo targeting strategies.
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Discussion
We have now utilized several independent methods to investigate the
mechanisms of DNA repair choice during in vivo genome editing in both neonatal and
adult mice. While PCR analysis showed that both NHEJ and HDR contribute to the
observed phenotype, these results were largely non-quantifiable.
Our results with a novel Dual Reporter to assess HDR and NHEJ revealed a
preference for HDR in neonatal mice. Unfortunately, the Dual Reporter did not yield as
interpretable results in adult mice. A notable difference between the hF9 and Dual
Reporter is the requirements for expression are more restrictive for hF9 donors, since
they lack the first exon of F9 (which provides the signal peptide). Secretion of hF.IX
protein cannot result from basal expression from the ITR’s (weak) promoter activity. Off
target integration could lead to hF.IX production if the donor integrates in the forward
orientation of an expressed gene, as long as the mature mRNA transcript is in the
correct reading frame. Indeed, we observed evidence of expression deriving from mice
treated with ZFN + hF9-Donor in mice lacking the hF9mut target site, associated with off
target cleavage within another gene expressed in liver (see chapter 2, Figure 2.9). In
contrast, the Dual Reporter design is expected to share the requirement for in frame
splicing, but since it contains a 2A sequence and the full CD8 open reading frame,
expression derived from ITR promoter activity can not be ruled out, and was observed in
adult mice treated with Mock + Dual Reporter. In a small pilot experiment (data not
shown), we observed a reduction in CD8 expression after performing partial
hepatectomy on mice treated with Dual Reporters, consistent with this hypothesis. CD8
expression was higher in mice treated with ZFN, however the values were not
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consistently statistically significant between WT mice and hF9mut mice harboring the
ZFN target site, suggesting off target expression made a substantial contribution to this
expression. Alternatively, other changes to a cell undergoing sustained DNA damage
(both on and off target) could have driven increased expression relative to the Mock
control).
Experiments comparing expression derived from homologous and nonhomologous donors corroborated the results of the Dual Reporter experiments. Armed
with a reproducible system to easily read out indicators of NHEJ and HDR mediated
repair, we were able to further investigate the molecular requirements of in vivo genome
editing of the liver. In addition, with the knowledge that HDR is playing a substantial role
in targeting in neonatal livers, we were able to employ strategies to push the DNA repair
choice balance heavily in the direction of HDR using ZFNickases.
As off target DNA damage and unintended integrations are the primary concern
for in vivo genome editing, these experiments provide a useful tool to quantify the
specificity of targeted gene addition. Using the readout of hF.IX expression from nonhomologous donor as a “worst case” scenario with respect to untemplated integration,
we estimate that the HDR/NHEJ ratio is improved by at minimum 17 fold using
ZFNickases than with ZFNs. Additional qPCR analysis could be helpful in determining
the full extent of this difference, as we were bound by the lower limit of detection of hF.IX
in plasma. In settings where it is possible to use HDR therapeutically (e.g. when the
donor cassette can be comfortably packaged with homology arms within an AAV vector,
and when the target tissues are dividing), arms of homology would provide a second
constraint (in addition to the specificity of the nuclease) limiting off-target integration.
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The Prkdcscid/scid mutation did not appear to reduce HDR in mice treated as
neonates, however homology-independent vector integration was largely diminished
(~20 fold). These data are consistent with the known role of DNA-PKcs in processing
DNA hairpins, like those present in the AAV ITRs, which could limit the extent of NHEJ
mediated integration at the target site (and presumably off-target sites as well). Further
studies are warranted to determine whether transient inhibition of NHEJ factors would
provide an overall reduction in random integration, since the current body of literature
describes mixed effects of NHEJ inhibition in mouse liver (no effect, (Paulk, Marquez
Loza, Finegold, & Grompe, 2012); increased integration, (Song et al., 2004)). Specifically
inhibiting the processing of ITR hairpins could have important advantages over
obstructing NHEJ globally. This would be ideal for maximizing the specificity and safety
of in vivo gene correction: limiting homology-independent AAV integration without
preventing NHEJ repair of other (spontaneous or nuclease-induced) double strand
breaks.
These data point to homology directed recombination as the primary mechanism
of protein production from genome editing in neonatal mouse liver, and suggest large
gains can be made in both efficacy and specificity through deeper understanding of the
molecular determinants of this therapeutic approach.
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Figure 4.1

Figure 4.1 Sche matic of NHEJ and HR-me diate d Inte gration at the hF9mut
targe t locus.

Expected outcome of HDR mediated genome engineering (middle) and NHEJ mediated
vector integration in the forward orientation (bottom). Red lines above illustrations
represent splicing to generate wild-type hF9 transcript.
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Figure 4.2

Figure 4.2 PCR De te ction of Bands Consiste nt with NHEJ and HR Me diate d
Re pair of hF9mut locus.

PCR detection of ~2.8kb and ~2.0kb bands consistent with NHEJ and HDR,
respectively, using primers annealing within the genome and the donor (as illustrated in
upper panel). Lower band appears in the presence of donor, and appears to be due to
amplification with one primer.
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Figure 4.3

Figure 4.3 Dual Re porte r Sche matic.

Layout of CD8/CD4 Dual Reporter (designated with AAV) and expected outcomes of
HDR (upper) and NHEJ (lower) mediated integration within the hF9mut locus. In the
case of HDR, only the CD4 expression cassette flanked by arms of homology is
expected to be inserted, resulting in expression of human CD4 on the surface of
hepatocytes. Vector integration (in the forward orientation) is expected to integrate the
entire AAV cassette, and lead to expression of hCD8. Skipping of the splice site,
resulting in hCD4 expression from homology independent integration is a formal
possibility, however does not appear to occur frequently based on transient transfection
experiments presented in Figure 4.4.
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Figure 4.4
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Figure 4.4 In Vitro Validation of Dual Re porte r Expre ssion Casse tte s.

Transient transfection of HEK293T cells with plasmids approximating various outcomes
that could potentially arise from Dual Reporter integration. Fluorescence measured by
flow cytometry using CD4-PE and CD8-APC conjugated antibodies. Cells gated on
FSC/SSC (size/granularity) (left), single cells, GFP expression (FITC channel) (middle),
and finally by CD4-PE/CD8-APC fluorescence intensity (right). (A) Untransfected. (B)
PGK-GFP only (transfection control). (C) SA—2A—CD8 expression driven by CMV
promoter used in all expression cassettes. (D) SA—2A—CD4 expression. (E) Double
transfection with plasmids represented in panels C and D, demonstrating the ability to
identify double positive populations. (F) Measurable expression of only hCD8 in cells
transfected with SA—2A—CD8—(Homology Arm)—SA—2A—CD4 cassette, suggesting
splice skipping is suppressed due to the strong polyadenylation sequence of the hCD8
expression cassette.
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Figure 4.5

Figure 4.5 In Vivo Validation of Dual Re porte r Expre ssion Casse tte s.

Representative flow cytometry plots demonstrating CD4 and CD8 expression in mice
treated with hydrodynamic tail vein injection of saline (top panel), SA—2A—CD8
expression cassette (middle panel), or SA—2A—CD4 cassette (bottom panel). Cells
were isolated from mice by 2-step collagenase perfusion and stained for analysis using
flow cytometry. Gated on hepatocytes SSC/FSC (left panels). PE-hCD4 (center panels)
and APC-hCD8 (right panels) markers are relative to FITC (y axis), which represents the
strong autofluorescence observed in primary hepatocytes.
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Figure 4.6
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Figure 4.6 CD8/CD4 Expre ssion in Mice Tre ate d as Ne onate s with ZFN and
Dual Re porte r

hF9mut neonates were treated with 5x1010 vg AAV8-ZFN/Mock and 2.5x1011 vg AAV8Dual-Reporter, doses identical to previously described experiments in neonatal mice (Li
et al., 2011). Robust CD4 expression (indicative of HDR) was detected only in mice
treated with ZFN and Dual Reporter and also harbored the hF9mut target site (center).
CD8 expression (indicative of NHEJ mediated vector integration) was measurable but
did not appear to differ substantially between groups.
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Figure 4.7

Figure 4.7 Magne tic Be ad Enrichme nt of CD4 Expre ssing He patocyte s

(A) Flow cytometric plots of primary hepatocytes pooled from mice treated with ZFN and
Dual Reporter. Upper: Unenriched. Middle: First column. Lower: Second column,
resulting in almost 50% CD4+ hepatocytes. (B) Schematic representing probe and
expected bands indicative of untargeted allele and HDR-mediated integration of Dual
Reporter. (C) Southern blot demonstrating band consistent with HDR in the enriched
(CD4+ column) but not unenriched (Neg) column.
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Figure 4.8
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Figure 4.8 CD8/CD4 Expre ssion in Mice Tre ate d as Ne onate s with ZFN and
Dual Re porte r

Mice were treated with 1x1011 vg ZFN and 5x1011 vg Dual Reporter via tail vein injection,
identical to the majority of the experiments conducted with hF9 donors. In all groups,
CD8 expression was greater than that observed in mice treated as neonates. CD4
Expression appeared to be greater in mice harboring the hF9mut cassette and receiving
ZFN.
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Figure 4.9
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Figure 4.9 Adult Mice Tre ate d With ZFN and Donors With and Without
Homology

Adult mice treated with 1x1011 vg ZFN and 5x1011 vg Donor with and without arms of
homology. (A) hF9mut mice treated with N2 ZFNs (targeting human F9), reproduced
from figure 2.7A: No statistically significant difference in expression between mice
treated with homologous donor (blue, human F9 arms of homology) and nonhomologous donor (red, mAlb arms of homology). (B) WT mice treated with mAlb ZFNs:
No statistically significant difference in expression between mice treated with
homologous donor (blue, mAlb arms of homology) and non-homologous donor (red,
human F9 arms of homology).
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Figure 4.10

Figure 4.10 Mice Tre ate d as Ne onate s With ZFN and Donors With and Without
Homology

Mice treated as neonates via retro-orbital injection with 1x1011 vg ZFN and 5x1011 vg
Donor with and without arms of homology. (A) hF9mut mice treated with N2 ZFNs: 10
fold greater expression in mice treated with homologous donor (blue, human F9 arms of
homology) vs those treated with non-homologous donor (red, mAlb arms of homology).
(B) WT mice treated with mAlb ZFNs: 6-10 fold difference in expression between mice
treated with homologous donor (blue, mAlb arms of homology) and non-homologous
donor (red, human F9 arms of homology).
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Figure 4.11
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Figure 4.11 Prkdc
Homologous donors

Mice Tre ate d as Ne onate s With Homologous and non-

Mice treated as neonates via retro-orbital injection with 1x1011 vg ZFN and 5x1011 vg
Donor with and without arms of homology. Blue: Similar levels of expression to WT mice
treated with similar doses (see Figure 4.10). Red: Substantially reduced expression in
mice treated with non-homologous donors.
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Figure 4.12
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Figure 4.12 hF9mut Mice Tre ate d With ZFN or ZFNickase and Homologous or
Non-homologous Donors

(A) Mice treated as neonates via retro-orbital injection with 1x1011 vg ZFN/ZFNickase
and 5x1011 vg Donor with and without arms of homology. Plasma hF.IX concentrations
shown 4 weeks post treatment. As observed previously, ZFNs elicit robust levels of
expression with homologous donor (blue), and ~10-fold less with non-homologous donor
(red). ZFNickases induced roughly 4-fold less expression with homologous donor
(green), with levels that were undetectable with non-homologous donor (clear). (B) Mice
treated as neonates via retro-orbital injection with 1x1011 vg ZFN and 5x1011 vg
homologous donor or 4x1011 vg ZFN and 5x1011 vg Donor with and without arms of
homology. ZFN treated animals with homologous donor exhibited the highest levels of
expression (blue), however at an increased dose ZFNickase + homologous donor
treated animals demonstrated robust levels of hF.IX expression approaching 40% of
normal (green). hF.IX was not detected in the plasma of mice treated with ZFNickase +
non-homologous donor (clear).
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS
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The results described in the preceding chapters indicate that multiple DNA repair
mechanisms are capable of mediating efficient site-directed integration of a therapeutic
transgene in the liver. Further, a broader understanding of the molecular underpinnings
of this process is likely to reveal new approaches to increase the efficacy and specificity
of in vivo genome editing. Historically, the term gene targeting has been used
synonymously with HDR mediated insertion of a desired transgene, the less common
DSB repair pathway in mammals. Although HDR is capable of error-free repair using an
appropriate template, there are circumstances when it may be either inactive (quiescent
cells) or incapable (large transgenes that cannot be packaged with homology arms) of
promoting therapeutic levels of therapeutic donor integration. The more active pathway,
NHEJ, is often defined as the “error prone” repair choice, useful only for gene disruption.
It is worth noting that nucleases are very processive, and will continue to cleave their
recognition site until it is destroyed by small insertions and deletions. Since these
“indels” are the most common method to quantify NHEJ, it is hard to determine the
number of times a break is repaired perfectly in living cells (Bétermier, Bertrand, &
Lopez, 2014).
In our studies, we find NHEJ is capable of efficient integration of a therapeutic
transgene, and may contribute to nearly all of the observed protein expression in mice
treated as adults. This would be an intriguing approach to treat diseases caused by
deficiencies in genes much larger than the AAV packaging capacity. Instead of replacing
an entire gene, a large exon corresponding to the disease mutation could be inserted
into an intron to generate wild type mRNA through splicing.
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HDR appears to be responsible for the majority of expression in mice treated as
neonates, opening many avenues to further improve this preference in order to maximize
the safety profile of liver genome editing. By the same logic of substituting nickases for
nucleases, it may be possible to stimulate HDR repair using enzymes with even less
genotoxic potential, for example through chromatin remodeling. The next generation of
HDR promoting reagents will benefit from unraveling of the still incompletely
characterized mechanisms of DSB repair in mammalian cells.
Off target cleavage and the potential for off target integration are the most
important safety concerns for genome editing using DNA modifying enzymes, and future
directions will include development of strategies to reduce these unwanted events. This
is true for ZFNs, as well as other reagents that have been described since these studies
were initiated, including clustered regulatory interspaced short palindromic repeat-based
CRISPR/Cas9 nucleases. While it is encouraging that phenotypic correction of diseases
is possible without observing overt toxicity, the studies presented were not powered to
demonstrate smaller differences in health outcomes. As the technology and technical
knowledge required to perform high throughput sequencing of viral integrations (or even
entire genomes) continues to improve, we will have the ability to detect increasingly rare
off target events(Gabriel et al., 2011; Li et al., 2010).
One improvement that could be made is a technique to regulate expression of
the nuclease, since there is no benefit to continuous expression subsequent to its role in
editing of the genome. One solution would be to include the ZFN target site within the
expression cassette that would be translated as an N-terminal fusion to the ZFN
monomers, such that indels due to cleavage would likely disrupt the open reading frame.
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The advantage of this solution is that it would act as a feedback loop, allowing ZFNs to
inactivate themselves only when the levels of expression are sufficient for their activity
(and thus would still function at their target site). In addition, this would not unnecessarily
complicate the approach, as opposed to methods that require expression of
transactivators or repressors, each with their own potential safety implications. The main
disadvantages are: (i) Inclusion of the target sequence would need to be within the open
reading frame, and thus must be compatible with functional nuclease activity. Since
ZFNs are often fused with an N-terminal 3xFLAG tag, and the target sequence could be
inserted in multiple ways (two orientations, each with 3 reading frames), it is likely this
limitation would be overcome in most cases. (ii) Inactivation through indel formation may
efficiently eliminate ZFN expression, although it would not necessarily stop the
translation of a novel polypeptide (due to frame shift). In this case, the strategy may
mitigate the safety concerns of off-target nuclease activity, but not the potential for neoantigen expression to trigger an immune response against transduced cells. Ideally,
advances in delivery technologies like mRNA conjugates could address both issues by
allowing transient delivery of nucleases without AAV. Together with AAV-based delivery
of the donor, which does not contain an enhancer or promoter, this approach would
substantially reduce the possibility of integration mediated oncogene activation.
An important consideration is that unlike simpler drugs such as small molecule
inhibitors, where it is more likely the drug interacts similarly with the human target and its
homologue in an animal model, the nature of DNA modifying reagents means the exact
sequence of the target genome will be very important in determining off target activity.
Even with sensitive assays capable of detecting miniscule levels of unintended cleavage,
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the specific off targets will likely be the most important factors in determining the
oncogenic risks of these approaches. Although it is of great scientific interest to draw
conclusions about differences in specificity of different classes of nucleases, it is clear
that our current understanding is insufficient to fully predict genotoxic risks. For example,
mouse studies of HSC transplantation following retroviral transduction, even with human
cells, do not always predict specific risks of clonal outgrowth seen in human trials
(Cavazzana-Calvo et al., 2010). On the other hand, in one of the largest natural
experiments of the molecular biology era, millions of humans infected with HIV possess
trillions of lentiviral integrations in their CD4 T-cells. Given the clinical experience in HSC
gene therapies, we might have expected a substantial number of HIV infected patients to
develop viral integration mediated leukemias, yet this does not appear to be the case.
There is great therapeutic potential for genome editing to correct many debilitating
illnesses, especially in dividing tissues, where episomal AAV expression is unlikely to
persist. The therapeutic potential of DNA modifying reagents must be optimized and
evaluated empirically, weighing the potential risks as well as the costs of inaction in the
face of devastating diseases.
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